

 Open access • Posted Content • DOI:10.1101/2021.01.04.425347

Cortico-autonomic local arousals and heightened somatosensory arousability during NREM sleep of mice in neuropathic pain — [Source link](#)

Anita Lüthi, Romain Cardis, Sandro Lecci, Laura M. J. Fernandez ...+4 more authors

Institutions: University of Lausanne

Published on: 07 Jan 2021 - bioRxiv (Cold Spring Harbor Laboratory)

Topics: Non-rapid eye movement sleep, Chronic pain and Neuropathic pain

Related papers:

- [Cortico-autonomic local arousals and heightened somatosensory arousability during NREMS of mice in neuropathic pain.](#)
- [Pain Perception – Nociception during Sleep](#)
- [Current Views on Chronic Pain and Its Relationship to the State of Sleep](#)
- [Sleep arousal response to experimental thermal stimulation during sleep in human subjects free of pain and sleep problems.](#)
- [Effects of Aging on Cortical Neural Dynamics and Local Sleep Homeostasis in Mice](#)

Share this paper:    

View more about this paper here: <https://typeset.io/papers/cortico-autonomic-local-arousals-and-heightened-9agy8pzylx>

1 **Cortico-autonomic local arousals**
2 **and**
3 **heightened somatosensory arousability during**
4 **NREM sleep of mice**
5 **in**
6 **neuropathic pain**

7
8 Romain Cardis^{1,2}, Sandro Lecci¹, Laura M.J. Fernandez¹, Alejandro Osorio-
9 Forero¹, Paul Chu Sin Chung^{1,2}, Stephany Fulda^{3,*}, Isabelle Decosterd^{1,2,*},
10 Anita Lüthi^{1,*}

11 *shared senior authorship and correspondence

12 Address:

13 ¹Department of Fundamental Neurosciences, Rue du Bugnon 9, CH-1005 Lausanne

14 ²Pain Center, Department of Anesthesiology, Lausanne University Hospital (CHUV), Lausanne,
15 Switzerland

16 ³Sleep and Epilepsy Center, Neurocenter of Southern Switzerland, Civic Hospital (EOC) of Lugano,
17 Lugano, Switzerland.

18
19 **Manuscript info:**

20 Number of figures: 7

21 Number of Supplementary figures: 4

22 Number of words in abstract: 149

23 Number of words in main text including legends: 9,579

24 Number of words in legends: 3,093

25 Number of references: 85

26 Abstract

27 **Chronic pain patients frequently suffer from sleep disturbances. Improvement of sleep quality alleviates**
28 **pain, but neurophysiological mechanisms underlying sleep disturbances require clarification to advance**
29 **therapeutic strategies. Chronic pain causes high-frequency electrical activity in pain-processing cortical**
30 **areas that could disrupt the normal process of low-frequency sleep rhythm generation. We found that**
31 **the spared-nerve-injury (SNI) mouse model, mimicking human neuropathic pain, had preserved sleep-**
32 **wake behavior. However, when we probed spontaneous arousability based on infraslow continuity-**
33 **fragility dynamics of non-rapid-eye-movement sleep (NREMS), we found more numerous local cortical**
34 **arousals accompanied by heart rate increases in hindlimb primary somatosensory, but not in prelimbic,**
35 **cortices of SNI mice. Closed-loop mechanovibrational stimulation revealed higher sensory arousability**
36 **in SNI. Sleep in chronic pain thus looked preserved in conventional measures but showed elevated**
37 **spontaneous and evoked arousability. Our findings develop a novel moment-to-moment probing of**
38 **NREMS fragility and propose that chronic pain-induced sleep complaints arise from perturbed**
39 **arousability.**

40 Introduction

41 Pain causes functional impairment, displeasure and stress and can impede even the simplest daily
42 life routines, including sleep. If not treated, pain has the ability to outlast its original cause, producing
43 chronic pain that is generally difficult to treat (Finnerup *et al.*, 2015; Treede *et al.*, 2019). Current estimates
44 are that more than two out of three individuals suffering from chronic pain also show diverse symptoms
45 characteristic for insomnia disorders, such as lower sleep efficiency, more time awake after sleep onset
46 and frequent brief awakenings during the night (Bjurstrom & Irwin, 2016; Mathias *et al.*, 2018). The
47 relation between chronic pain and sleep disruptions is complex and bidirectional, but accurate assessment
48 of sleep problems is considered critical to antagonize the perpetuation of pain (Bjurstrom & Irwin, 2016).
49 Therefore, key mechanisms associating pain with sleep disturbance need to be clarified.

50 Animal models of chronic pain that mimic clinical symptoms of human patients have been critical
51 to understand the pathophysiological mechanisms producing chronic pain states (Burma *et al.*, 2017).
52 Neuropathic pain is caused by damage to the somatosensory nervous system (Finnerup *et al.*, 2021) and
53 induced in rodents by surgically lesioning peripheral nerves, such as the sciatic nerve (Decosterd & Woolf,
54 2000; Bourquin *et al.*, 2006). Neuropathic pain causes maladaptive structural and functional remodeling
55 of the central and peripheral nervous systems, shifting brain circuits towards pain hypersensitivity and
56 aversive behavioral states (Kuner & Kuner, 2020). Hyperexcitability and an abnormal activity in a broad
57 range of gamma frequencies (30–100 Hz) in pain-processing cortical areas were found to be primary
58 culprits for the elevated sensitivity to painful stimuli and for aversive behaviors (Tan *et al.*, 2019), a finding
59 that is in line with observations in human (Ploner *et al.*, 2017). In contrast to these advances, sleep studies
60 on chronic pain models are scarce, used relatively simple sleep measures, and produced variable results
61 (Andersen & Tufik, 2003; Kontinen *et al.*, 2003; Tokunaga *et al.*, 2007; Cardoso-Cruz *et al.*, 2011; Leys *et al.*,
62 2013). Therefore, it is currently open whether these animal models are also suited to address the sleep
63 complaints of human patients.

64 One possibility is that current approaches have so far failed to uncover the full profile of the sleep
65 disruptions caused by chronic pain. Studies in insomnia disorders indeed suggest that changes in
66 traditional sleep parameters often seem not in line with the severity of the sleep complaints (Feige *et al.*,
67 2013; van Someren, 2020). Standard polysomnography describes sleep as a sequence of discrete states
68 and distinguishes between non-rapid-eye-movement sleep (NREMS) and rapid-eye-movement sleep
69 (REMS), with the former further subdivided into transitional (N1), light (N2) and deep (N3) stages (Iber *et al.*
70 *et al.*, 2007). Many reports on human patients find little change in the absolute or relative times spent in

71 these stages and/or their principal spectral characteristics (Salin-Pascual *et al.*, 1992; Perlis *et al.*, 2001b;
72 Buysse *et al.*, 2008; Wei *et al.*, 2017; Feige *et al.*, 2018; Christensen *et al.*, 2019; Lecci *et al.*, 2020). Instead,
73 cortical activity patterns are abnormally enriched in the alpha (8–12 Hz) (Krystal *et al.*, 2002; Riedner *et al.*
74 *et al.*, 2016), beta (18–30 Hz) (Krystal *et al.*, 2002; Spiegelhalder *et al.*, 2012; Maes *et al.*, 2014; Riedner *et al.*
75 *et al.*, 2016; Lecci *et al.*, 2020) and/or low-gamma bands (30–45 Hz) (Perlis *et al.*, 2001b; Lecci *et al.*, 2020),
76 in one or more NREMS stages and/or in REMS (Spiegelhalder *et al.*, 2012; Christensen *et al.*, 2019; Lecci
77 *et al.*, 2020) and/or in restricted brain areas (St-Jean *et al.*, 2012; Riedner *et al.*, 2016; Lecci *et al.*, 2020).
78 Such high-frequency electrical rhythms during sleep are part of a physiological state referred to as
79 “hyperarousal” (Feige *et al.*, 2013; van Someren, 2020; Vargas *et al.*, 2020) that has been related to less
80 restorative sleep (Moldofsky *et al.*, 1975; Krystal & Edinger, 2008), to misperceiving sleep as wakefulness
81 (Perlis *et al.*, 2001b; Lecci *et al.*, 2020), and to higher heart rates (Maes *et al.*, 2014), all of which are key
82 features of insomnia disorders in humans. Other studies applied various metrics and proposed more
83 spontaneous arousals and/or easier wake-ups in response to sensory stimulation (Parrino *et al.*, 2009;
84 Forget *et al.*, 2011; Wei *et al.*, 2017; Feige *et al.*, 2018). Taken together, the presence of high-frequency
85 electrical activity, combined with diverse measures of arousability, has been useful in clarifying the
86 pathophysiological mechanisms underlying insomnia disorders. To date, however, such measures have
87 not been applied to study sleep in chronic pain in humans and mice, and there is still a paucity of
88 comparative studies between sleep in chronic pain patients and in primary insomniacs (Bjurstrom & Irwin,
89 2016). Therefore, it is currently unclear whether chronic pain is accompanied by high-frequency cortical
90 activity during NREMS and whether this affects spontaneous and evoked arousability (Mathias *et al.*, 2018;
91 Kuner & Kuner, 2020).

92 This study pursues this question through implementing a real-time tracking method for
93 spontaneous and evoked arousability in the mouse spared-nerve-injury (SNI) model of neuropathic pain
94 (Bourquin *et al.*, 2006). We start from previously described fragility-continuity dynamics of NREMS in mice
95 and humans that indicate variable arousability on the ~50-sec time scale (Lecci *et al.*, 2017). The fragility-
96 continuity dynamics are present while NREMS remains polysomnographically continuous and manifest in
97 fluctuating activity of several brain and peripheral parameters, notably in the power of sleep spindles
98 (10–15 Hz) in the global EEG and the local field potential (LFP) signals. On this close-to-minute timescale,
99 we show here that we are capable of tracking spontaneous and evoked arousability across NREMS in the
100 resting (light) phase. We find that the sleep disruptions in SNI animals concern both, altered spontaneous
101 and evoked arousability. In particular, we identify a novel, previously undescribed cortico-autonomic

102 arousal that pairs EEG desynchronization with increased heart rate and that occurs more frequently in SNI
103 animals.

104

105 Results

106 SNI mice show normal sleep-wake behavior


107 SNI mice and Sham controls (n = 18 each) were first analyzed for their sleep-wake behavior using
108 standard polysomnography. EEG/EMG measurements were carried out prior to SNI and Sham surgery and
109 at post-surgical days 22-23 (D20+), a time point at which chronic pain is established (Decosterd & Woolf,
110 2000; Bourquin et al., 2006). At both time points, recordings lasted for 48 h under undisturbed conditions.
111 Based on these data, SNI and Sham controls spent similar amounts of time asleep in the 12 h-light and
112 dark phases, during both baseline and at D20+ (**Figure 1A**). Both treatment groups showed minor
113 increases (2.4-3 %) in NREMS time at the expense of wakefulness at D20+ compared to baseline in both
114 dark and light phases (mixed-model ANOVAs with factors ‘treatment’ and ‘day’, p = 0.0013 in light phase,
115 p = 8.5×10^{-6} in dark phase for ‘day’, p > 0.8 for ‘treatment’ for either light or dark phase, no interaction).
116 Moreover, cumulative distributions of NREMS and REMS bout lengths at D20+ were similar for Sham and
117 SNI, with only a minor shift toward smaller values in SNI for both NREMS (**Figure 1B**, -2.3 s; Kolmogorov-
118 Smirnov (KS) test, p = 0.015) and REMS (-3 s; KS test, p = 0.026). When subdivided into short, intermediate
119 and long bouts for the light phase, there were no significant differences between Sham and SNI for both
120 NREMS and REMS (**Figure 1B**, mixed-model ANOVAs for ‘treatment’ x ‘bout length’, p = 0.79 for NREMS,
121 p = 0.23 for REMS).

122 Furthermore, sleep onset latency (**Figure 1C**) and NREMS fragmentation by brief movement-
123 associated microarousals (MAs, defined in mouse as ≤ 16 s awakenings accompanied by movement
124 activity seen in the EMG, measured over 48 h) (**Figure 1D**) (Franken *et al.*, 1999), were not altered by
125 treatment or time post-surgery (mixed-model ANOVA with factors ‘treatment’ and ‘day’, for sleep onset
126 latency, p = 0.42 and p = 0.94, no interactions; for number of MAs, p = 0.79 and p = 0.43, no interactions).

127 We next investigated the mean spectral properties of each vigilance state through constructing
128 normalized power spectral densities (Vassalli & Franken, 2017) for the full 48 h-long recordings. Both
129 NREMS and REMS showed the respective characteristic spectral peaks at delta (1–4 Hz) and at theta
130 frequencies (5–10 Hz), respectively. These were indistinguishable between the two groups of animals
131 and from baseline to D20+ (**Figure 1E**).

132 We specifically evaluated power in the high-gamma frequency (60—80 Hz) range, a frequency band
133 linked to pain sensations when optogenetically induced in mouse (Tan et al., 2019). We found that relative
134 gamma power was increased in SNI at D20+ compared to baseline both in wake and in NREMS (**Figure 1F**,
135 1-sample *t*-test for wake and NREMS in SNI, $p = 0.011$ and $p = 0.0092$, respectively). The heart rate was
136 also higher in NREMS of SNI animals at D20+ compared to baseline (**Figure 1G**, mixed-model ANOVA with
137 factors ‘treatment’ x ‘state’ x ‘day’ with interaction, $p = 0.02$, *post-hoc* paired *t*-test for SNI in NREMS, $p =$
138 0.002 , with Bonferroni-corrected $\alpha = 0.0125$). A tendency was also evident in REMS, during which heart
139 rate was already elevated (**Figure 1G**, effect of ‘state’ in the ANOVA, $p = 0.003$, paired *t*-test in SNI in
140 REMS, $p = 0.027$). There were no correlations between relative changes in gamma power and alterations
141 in sleep architecture in individual mice (change in the number of MAs per h of NREMS x change in gamma
142 power; pairwise linear correlation $R^2 = 0.09$, $p = 0.08$; change in total NREMS time x change in gamma
143 power; $R^2 = 0.02$, $p = 0.36$).

144 These data indicate that SNI animals do not suffer from major alterations in sleep-wake behaviors.
145 Still, pain-related pathological changes in brain and periphery continued to be present in sleep. This is
146 consistent with a state of “hyperarousal” whereby high-frequency power components are
147 disproportionately elevated during sleep that is normally dominated by low-frequency rhythms (van
148 Someren, 2020; Vargas et al., 2020), and where heart rate also remains elevated. As such alterations could
149 affect arousability, we asked when and where in the brain this abnormal activity appeared. Furthermore,
150 we developed an approach to systematically quantify alterations in both, spontaneous and evoked, types
151 of arousability from NREMS during the resting phase.



152

153 **Figure 1** – Preserved sleep-wake behavior and spectral properties in SNI animals. **(A)** Mean percentage
 154 of total time spent in the three main vigilance states for Sham (n = 18) and SNI (n = 18) animals in light
 155 (left) and dark phase (right) in baseline (B) and at day 20+ (D20+) after surgery. Black lines connect data
 156 from single animals. The significant main effects and interactions from the ANOVAs are shown using

157 pictograms for factors and interaction. *Post-hoc* tests were done once interactions were significant.
158 Mixed-model ANOVA for non-rapid-eye-movement sleep (NREMS) in light phase: $F_{(1,34)} = 0.048$, $p = 0.82$
159 for 'treatment'; $F_{(1,34)} = 12.24$, $p = 0.0013$ for 'day'; $F_{(1,34)} = 2.5$, $p = 0.12$ for interaction. Mixed-model
160 ANOVA for NREMS in dark phase: $F_{(1,34)} = 0.009$, $p = 0.92$ for 'treatment'; $F_{(1,34)} = 27.409$, $p = 8.5 \times 10^{-6}$ for
161 'day'; $F_{(1,34)} = 0.379$, $p = 0.54$ for interaction. There were no significant effects in rapid-eye-movement
162 sleep (REMS). **(B)** Bout size cumulative distribution, (with Kolmogorov Smirnov (KS) test results) and time
163 spent in short, intermediate and long bouts for NREMS (left) and REMS (right) between Sham and SNI at
164 D20+. Mixed-model ANOVA for time in bouts (log transform for normality criteria) for NREMS: $F_{(2,68)} =$
165 0.23 , $p = 0.79$ for interaction, for REMS: $F_{(2,68)} = 1.5$, $p = 0.23$ for interaction. **(C)** Mean latency to sleep
166 onset (first consolidated NREMS). Mixed-model ANOVA $F_{(1,34)} = 0.7$, $p = 0.4$ for 'treatment'; $F_{(1,34)} = 0.006$,
167 $p = 0.94$ for 'day'; $F_{(1,34)} = 0.021$, $p = 0.88$ for interaction. **(D)** Number of microarousals (MAs) per h of
168 NREMS in light phase; Mixed-model ANOVA $F_{(1,34)} = 0.067$, $p = 0.8$ for 'treatment'; $F_{(1,34)} = 0.63$, $p = 0.43$
169 for 'day'; $F_{(1,34)} = 0.61$, $p = 0.44$ for interaction. **(E)** Normalized power spectrum for Sham and SNI for wake,
170 NREMS and REMS at baseline (left) and D20+ (right). Shaded errors are 95 % confidence intervals (CIs) of
171 the means. **(F)** High-gamma power (60–80 Hz) for D20+ relative to baseline (from the spectra shown in
172 E). One-sample *t*-test for wake in Sham: $t_{(16)} = 0.86$, $p = 0.4$; for wake in SNI: $t_{(16)} = 2.8$, $p = 0.011$. One-
173 sample *t*-test for NREMS in Sham: $t_{(16)} = 0.97$, $p = 0.34$; for NREMS in SNI: $t_{(16)} = 2.96$, $p = 0.0092$. One-
174 sample *t*-test for REMS in Sham: $t_{(16)} = 0.46$, $p = 0.64$; for REMS in SNI: $t_{(16)} = 2.62$, $p = 0.0184$. $\alpha = 0.0167$.
175 **(G)** Heart rate in NREMS (top) and REMS (bottom) from animals with suitable EMG signal, Sham ($n = 17$)
176 and SNI ($n = 14$). Mixed-model three-way ANOVA: $F_{(1,29)} = 0.5$, $p = 0.47$ for 'treatment'; $F_{(1,29)} = 70.4$, $p =$
177 3×10^{-9} for 'state', $F_{(1,29)} = 9.79$, $p = 0.003$ for 'day'; $F_{(1,1,29)} = 5.37$, $p = 0.02$ for interaction between the three
178 factors; *post-hoc* paired *t*-test in NREMS for baseline vs D20+ in Sham: $t_{(16)} = -0.4$, $p = 0.69$; SNI: $t_{(13)} = -$
179 3.75 , $p = 0.002$; paired *t*-test in REMS for baseline vs D20+ in Sham: $t_{(16)} = -1.9$, $p = 0.07$; SNI: $t_{(13)} = -2.4$, p
180 $= 0.027$; $\alpha = 0.0125$.


181

182 **The 0.02 Hz-fluctuation allows to probe variations in spontaneous arousability during NREMS**

183 Arousability in sleeping rodent, measured via external stimuli or through spontaneous arousals,
184 changes across the night (Neckelmann & Ursin, 1993; Wimmer *et al.*, 2012), and with variations in sleep
185 pressure (Franken *et al.*, 1999). For NREMS in early phases of the resting phase, we described a 0.02 Hz-
186 fluctuation during NREMS that provides a minute-by-minute time raster to measure arousability driven
187 by sensory stimuli. This fluctuation subdivides NREMS bouts into ~25 s-long periods of continuity and
188 fragility that show low and high sensory-evoked arousability, respectively (Lecci *et al.*, 2017; Yüzgeç *et al.*,
189 2018). To evaluate the utility of this fluctuation for measures of spontaneous arousability across the entire
190 light phase, we first tested whether MAs associated with muscular activity (**Figure 2A**), well-established
191 correlates for spontaneous arousability, were phase-locked to the 0.02 Hz-fluctuation in healthy mice (n
192 $= 30$ mice with 9,476 MAs). The onset of MAs coincided with declining or low sigma power levels that
193 followed a pronounced sigma power peak (**Figure 2B,C**), which is characteristic for a fragility period (Lecci
194 *et al.*, 2017; Fernandez & Lüthi, 2020). A spectral band typical for NREMS, such as delta (1–4 Hz) power,

195 showed a rapid decline preceding the MAs, indicating the momentary interruption of NREMS. The phase
196 values of the 0.02 Hz-fluctuation, calculated via a Hilbert transform (**Figure 2 – figure supplement 1**),
197 showed that MA onset times clustered around a mean preferred phase of $151.6^\circ \pm 1.1^\circ$, with 180°
198 representing the sigma power trough (Rayleigh test, $p < 1 \times 10^{-16}$). The majority of MAs (89 %) was clustered
199 between 90° – 270° , which narrows the fragility period to the low values of sigma power around the trough
200 (Lecci et al., 2017). The phase-locking was also observed when time points at 4, 8 and 12 s before the
201 onset of a MA were quantified (**Figure 2D**). This shows that the onset of the fragility period preceded the
202 MA. Fragility periods thus constitute moments during which MAs preferentially occur.

203 These phase relations persisted for all 1-h intervals across time-of-day (**Figure 2E**), although the
204 density of MAs showed a characteristic increase towards the end of the light phase and was higher during
205 the dark phase (**Figure 2F**). The peak frequency of the 0.02 Hz-fluctuation also remained relatively
206 constant, with a minor decrease in power during the dark phase (**Figure 2G**). Across the 24-h cycle, a
207 median of 33.6 % of all fragility periods were accompanied by a MA (**Figure 2H**). In sum, fragility periods
208 are permissive windows for MAs. This means that MAs appeared predominantly during fragility periods,
209 while a majority of fragility periods occurred with NREMS remaining consolidated.




210

211 **Figure 2** – MAs, indicating spontaneous arousability, are time-locked to the trough of the 0.02 Hz-
 212 fluctuation, corresponding to the NREMS fragility period. **(A)** Example of a MA (underlain in grey) defined
 213 by both a desynchronization in the EEG (top) and a burst of EMG activity (bottom) of length <16 s. The
 214 MAs were scored visually, and the onset was set at the beginning of phasic EMG activity (black vertical
 215 line). **(B)** Continuous sigma (red; 10–15 Hz) and delta (blue; 1–4 Hz) power in a NREMS period with MAs
 216 (grey-shading as in panel A). Note their occurrence during descending / low values of sigma power. **(C)**
 217 Mean sigma and delta power dynamics preceding the onset of a MA. **(D)** Histograms of the phase angle
 218 values of the 0.02 Hz-fluctuation at specific time points relative to the onset of a MA. The red line
 219 represents the corresponding phase of the fluctuation at each bin. A total of $n = 9,476$ MAs from 30 un-
 220 operated C57Bl/6J animals were included across the light-dark cycles for all analyses in this figure.
 221 Rayleigh tests and preferred phases \pm 95% CI for MA onset: $z = 4214.7$, $p < 1 \times 10^{-16}$, $m = 151.5 \pm 1.1^\circ$; for 4
 222 s before MA onset: $z = 3489$, $p < 1 \times 10^{-16}$, $m = 119.1 \pm 1.2^\circ$; for 8 s before MA onset: $z = 1416$, $p < 1 \times 10^{-16}$,
 223 $m = 85.3 \pm 2.0^\circ$; for 12 s before MA onset: $z = 548.163$, $p < 1 \times 10^{-16}$, $m = 50.1 \pm 3.3^\circ$. **(E)** Preferred phase of
 224 the 0.02 Hz-fluctuation at MA onset across time-of-day in hourly bins (dark phase, shaded, ZT, Zeitgeber
 225 time). **(F)** Density of MAs (per h of NREMS) across the light-dark cycle. **(G)** Parameters of the 0.02 Hz-
 226 fluctuation (frequency at peak and power, see inset for illustration) across the light-dark cycle. **(H)**
 227 Proportion of fragility periods (corresponding to values from 90 to 270°, see panel D) containing a MA.

228 **NREMS in SNI conditions shows normal phase-coupling of MAs to the 0.02 Hz-fluctuation**

229 We next evaluated SNI and Sham animals regarding the MAs and their coupling to the 0.02 Hz-
230 fluctuation. The 0.02 Hz-fluctuation was not different between Sham and SNI (n = 18 for both groups)
231 across the light phase. Thus, neither its amplitude nor frequency (**Figure 3A-C**), or, equivalently, the
232 number of its cycles per h of NREMS, were different between the groups (**Figure 3D**). The phase-coupling
233 to MAs was also unaltered (**Figure 3E**, mean angle \pm 95% CI: 152.3 ± 1.4 for Sham and 150.4 ± 1.3 for SNI)
234 and the distribution of fragility periods containing transitions to MAs, to REMS, or with continuation into
235 NREMS was indistinguishable (**Figure 3F**).

236 It has been shown that sleep loss exacerbates pain (Alexandre *et al.*, 2017). Sleep could thus be
237 relatively more disrupted in SNI animals after a period of sleep loss. We therefore carried out a 6 h-sleep
238 deprivation (SD) at the beginning of the light phase as done previously in the lab (n = 12 for Sham and SNI
239 each) (Kopp *et al.*, 2006). We confirmed a characteristic rebound of delta power (**Figure 3G,H**) and a
240 decrease in the frequency of MAs (**Figure 3I,J**, mixed-model ANOVA with factors ‘treatment’ and ‘SD’, p =
241 0.35 and p = 1.23×10^{-7} with no interaction). The phase-coupling of MAs to the 0.02 Hz-fluctuation
242 remained unaltered in both groups even with high sleep pressure (**Figure 3K,L**). Conditions of SNI thus left
243 spontaneous MAs, their coupling to the 0.02 Hz-fluctuation, as well as homeostatic regulation of
244 spontaneous arousability unaltered.



245

246 **Figure 3** – The 0.02 Hz-fluctuation and its relationship to MAAs were preserved in SNI animals, even when
 247 sleep pressure was high. (A-B) Representative traces of sigma power dynamics in a Sham (A) and a SNI (B)
 248 animal. Hypnograms shown below for W, wakefulness; N, NREMS; R, REMS. The circles represent the
 249 individual cycle detection used in D and F (see methods). (C) Power in the infraslow range for Sham and
 250 SNI (n = 18 each); shaded areas represent 95% CIs. (D) Another measure of the 0.02 Hz-fluctuation,
 251 calculated as number of cycles per h of NREMS. Data are shown for D20+ only, but baseline data points

252 were considered for statistical analysis. Mixed-model ANOVA: $F_{(1,34)} = 0.012$, $p = 0.91$ for ‘treatment’; $F_{(1,34)}$
253 $= 0.003$, $p = 0.95$ for ‘day’; $F_{(1,34)} = 2.17$, $p = 0.14$ for the interaction. (E) Histograms of the phase values of
254 the 0.02 Hz-fluctuation at MA onset for Sham and SNI, same as Figure 2D. Vertical lines denote mean
255 direction \pm 95% CI for Sham: 152.3 ± 1.4 ; SNI: 150.4 ± 1.3 . (F) Proportion of fragility periods (defined by
256 0.02 Hz-fluctuation phase values of $90\text{--}270^\circ$) containing a MA, continuing into NREMS or containing a
257 transition to REMS. Mixed-model ANOVA: $F_{(1,34)} = 0.17$, $p = 0.67$ for ‘treatment’; $F_{(2,68)} = 550.8$, $p = 2 \times 10^{-16}$
258 for ‘state’; $F_{(2,68)} = 0.59$, $p = 0.55$ for interaction. (G) Delta power dynamics across two light and dark phases
259 and after a 6 h-sleep deprivation. SD, Sleep deprivation, Rec, Recovery period, Ctrl control periods with
260 corresponding ZT values. Delta power values are normalized to the mean of those at ZT9-12. Shaded areas
261 represent SEM. SD was carried on a subset of 12 Sham and 12 SNI from the 18 shown in A–F, directly
262 following the D20+ recording. (H) Boxplot for delta power values during Rec. One-sample *t*-test for Sham:
263 $t_{(11)} = 17.2$, $p = 2.6 \times 10^{-9}$; SNI: $t_{(11)} = 16.48$, $p = 4.2 \times 10^{-9}$; between Sham and SNI two-sample *t*-test: $t_{(22)} = -$
264 0.6 , $p = 0.52$; $\alpha = 0.0125$. (I, J) As panels G, H for the number of MAs per h of NREMS. (J) Mixed-model
265 ANOVA: $F_{(1,22)} = 0.9$, $p = 0.35$ for ‘treatment’; $F_{(1,22)} = 58.52$, $p = 1.2 \times 10^{-7}$ for ‘SD’; $F_{(1,22)} = 0.12$, $p = 0.72$ for
266 interaction. (K, L) As panels G, H, for the preferred phase of the 0.02 Hz-fluctuation at MA onset. (L) Mixed-
267 model ANOVA: $F_{(1,22)} = 3.08$, $p = 0.09$ for ‘treatment’; $F_{(1,22)} = 1.45$, $p = 0.24$ for ‘SD’; $F_{(1,22)} = 5.72$, $p = 0.025$
268 for interaction. No significance in paired *post-hoc t*-tests.


269

270 **NREMS in SNI conditions shows a novel type of cortical local arousal**

271 In human NREMS, spontaneous arousals are an important measure for the severity of sleep
272 disorders and are primarily described by EEG desynchronization (Bonnet *et al.*, 1992; Azarbarzin *et al.*,
273 2014). In contrast, the scoring of a MA in mice requires concomitant muscular activity by convention
274 (Franken *et al.*, 1999). We hence tested whether the 0.02 Hz-fluctuation could serve to identify previously
275 undescribed arousal types in mice with characteristics distinct from conventional MAs. For this, we
276 generated spectral profiles of all cycles of the 0.02 Hz-fluctuation that were devoid of MAs. To take into
277 account the possibility that there were local events delimited to certain cortical regions (Nobili *et al.*, 2011;
278 St-Jean *et al.*, 2012; Riedner *et al.*, 2016; Lecci *et al.*, 2017), we combined polysomnography with
279 stereotaxically guided local field potential (LFP) recordings, as done previously in the lab (**Figure 4A,B**)
280 (Fernandez *et al.*, 2018). We chose the S1 hindlimb (S1HL, 5 Sham and 9 SNI) cortex (**Figure 4C,D**) that is
281 the site of sensory discrimination of pain and the prelimbic (PrL, 6 Sham and 8 SNI) cortex (**Figure 4I,J**)
282 that is concerned with aversive pain feelings in rodents (Kuner & Kuner, 2020) and in its homologue in
283 humans (Moisset & Bouhassira, 2007).

284 Local field potential recordings reliably reported on the 0.02 Hz-fluctuation in these two areas.
285 Consistent with its predominant expression in sensory cortices (Lecci *et al.*, 2017), the 0.02 Hz-fluctuation
286 showed a higher peak in S1HL than in PrL (**Figure 4A,B**). The cycles of successive continuity and fragility
287 periods were extracted (**Figure 2, figure supplement 1**) and their spectral dynamics plotted separately for

288 the relative contribution of power in the low-frequency delta (1—4 Hz) and the beta (16—25 Hz), low-
289 (26—40 Hz) and high- (60—80 Hz) gamma bands (**Figure 4E-H** for S1HL, **Figure 4K-N** for PrL). Average
290 values for the infraslow phase angles between 90—270°, corresponding to the fragility period enriched in
291 MAs (see **Figure 2**), and for the continuity period (from 270—90°), were calculated. Such analysis revealed
292 SNI- and region-specific alterations in the contributions of these bands to total power that were clearly
293 present in S1HL, but not detectable in PrL. In S1HL, delta power levels were decreased compared to Sham
294 (**Figure 4E**) whereas high-frequency components in the beta and the low-gamma range were elevated
295 (**Figure 4F-G**). Remarkably, delta power differences between Sham and SNI varied between fragility and
296 continuity periods (**Figure 4E**, mixed-model ANOVA with factors ‘treatment’ and ‘period’, $p = 0.001$ for
297 the interaction). In Sham, there was a distinct rapid upstroke of power in this frequency band that reached
298 a peak during the fragility periods (**Figure 4E**, *post-hoc t-test* for delta power in fragility vs continuity
299 period in Sham, $p = 0.001$). Fragility periods continuing into NREMS were thus clearly distinct from the
300 ones associated with MAs during which there is muscular activity and a decrease in EEG delta power (see
301 **Figure 2C**). In SNI animals, in contrast to Sham, there was no detectable elevation in delta power during
302 fragility periods continuing into NREMS (**Figure 4E**, *post-hoc t-test* in SNI, $p = 0.44$). The high-frequency
303 bands in the beta and low-gamma range instead showed a tonic increase in SNI that was present
304 throughout continuity and fragility periods (**Figure 4F-G**, mixed-model ANOVA with factors ‘treatment’
305 and ‘period’, for beta, $p = 0.01$, $p = 1.3 \times 10^{-9}$ and for low gamma, $p = 0.0053$, $p = 1.4 \times 10^{-10}$) and that was
306 also present, although to a milder extent, in the high-gamma range (**Figure 4H**).



307

308 **Figure 4** – SNI animals present locally disrupted spectral power dynamics during NREMS. (A–B) Sigma (10–
 309 15 Hz) and delta (1–4 Hz) dynamics during the same NREMS period in S1 hindlimb (HL) (A) and PrL (B)
 310 during a baseline recording. Hypnograms shown below. Circles represent peaks and troughs used to


311 detect the 0.02 Hz-fluctuation cycles (see Methods). Shaded areas indicate 0.02 Hz-fluctuation cycles that
312 are continuing uninterrupted in NREMS. Insets: Power spectrograms in the infraslow range, with Sham
313 and SNI overlapping. **(C)** Representative histological section confirming the location of recording site
314 through post-mortem electrocoagulation (arrowhead). **(D)** Anatomical sections summarizing histological
315 verification, with small circles showing recording sites for all animals included. Anteroposterior stereotaxic
316 coordinates are given relative to Bregma. **(E-H)** Trajectories of power in specific frequency bands
317 (indicated on top of graphs) across uninterrupted cycles of the 0.02 Hz-fluctuation, quantified in 20° bins.
318 Red line shows the corresponding 0.02 Hz-fluctuation phase. Boxplots quantify spectral power within
319 continuity (270—90°, red inverted U-shaped line) and fragility periods (90—270°, red U-shaped line). For
320 all bands, mixed-model ANOVA with factors ‘treatment’ and ‘period’ were done, followed by *post-hoc t*-
321 tests if applicable. Significance for main effects and/or interaction are shown by the presence of the
322 corresponding pictograms at the bottom left. These yielded **(E) for delta** $F_{(1,12)} = 7.16$, $p = 0.02$ for
323 ‘treatment’; $F_{(1,12)} = 18.5$, $p = 0.001$ for ‘period’; $F_{(1,12)} = 18.31$, $p = 0.001$ for interaction. *Post-hoc* for Sham
324 vs SNI in continuity: $t_{(12)} = 2.11$, $p = 0.055$; fragility: $t_{(12)} = 3.13$, $p = 0.0085$; and across periods for Sham: $t_{(4)}$
325 $= -7.9$, $p = 0.001$; SNI: $t_{(8)} = -0.8$, $p = 0.44$; $\alpha = 0.0125$; **(F) for beta** $F_{(1,12)} = 9.3$, $p = 0.01$ for ‘treatment’; $F_{(1,12)}$
326 $= 270.01$, $p = 1.3 \times 10^{-9}$ for ‘period’; $F_{(1,12)} = 1.01$, $p = 0.33$ for interaction. *Post-hoc* for Sham vs SNI in
327 continuity: $t_{(12)} = -2.5$, $p = 0.025$; fragility: $t_{(12)} = -3.43$, $p = 0.004$; and across periods for Sham: $t_{(4)} = 14.7$, p
328 $= 0.0001$; SNI: $t_{(8)} = 12.02$, $p = 2.1 \times 10^{-6}$; $\alpha = 0.0125$; **(G) for low-gamma** $F_{(1,12)} = 11.49$, $p = 0.0053$ for
329 ‘treatment’; $F_{(1,12)} = 398.35$, $p = 1.4 \times 10^{-10}$ for ‘period’; $F_{(1,12)} = 0.75$, $p = 0.4$ for interaction. *Post-hoc* for
330 Sham vs SNI in continuity: $t_{(12)} = -3.1$, $p = 0.008$; fragility: $t_{(12)} = -3.4$, $p = 0.0049$; and across periods for
331 Sham: $t_{(4)} = 18.6$, $p = 4.9 \times 10^{-5}$; SNI: $t_{(8)} = 14.39$, $p = 5.3 \times 10^{-7}$; $\alpha = 0.0125$; **(H) for high-gamma** $F_{(1,12)} = 3.31$, p
332 $= 0.09$ for ‘treatment’; $F_{(1,12)} = 94.38$, $p = 4.8 \times 10^{-7}$ for ‘period’; $F_{(1,12)} = 5.83$, $p = 0.03$ for interaction. *Post-*
333 *hoc* for Sham vs SNI in continuity: $t_{(12)} = -1.5$, $p = 0.14$; fragility: $t_{(12)} = -2.08$, $p = 0.059$; and across periods
334 for Sham: $t_{(4)} = 14.17$, $p = 1.4 \times 10^{-4}$; SNI: $t_{(8)} = 5.45$, $p = 6 \times 10^{-4}$; $\alpha = 0.0125$. **(I-N)** Analogous presentation for
335 PrL. Statistical analysis yielded: **(K) For delta** $F_{(1,12)} = 0.4$, $p = 0.5$ for ‘treatment’; $F_{(1,12)} = 11.99$, $p = 0.004$
336 for ‘period’; $F_{(1,12)} = 0.009$, $p = 0.92$ for interaction; **(L) for beta** $F_{(1,12)} = 0.56$, $p = 0.46$ for ‘treatment’; $F_{(1,12)}$
337 $= 127.5$, $p = 9.5 \times 10^{-8}$ for ‘period’; $F_{(1,12)} = 0.65$, $p = 0.43$ for interaction; **(M) for low-gamma** $F_{(1,12)} = 0.63$, p
338 $= 0.44$ for ‘treatment’; $F_{(1,12)} = 75.84$, $p = 1.5 \times 10^{-6}$ for ‘period’; $F_{(1,12)} = 0.93$, $p = 0.35$ for interaction; **(N) for**
339 **high-gamma** $F_{(1,12)} = 0.004$, $p = 0.94$ for ‘treatment’; $F_{(1,12)} = 9.49$, $p = 0.009$ for ‘period’; $F_{(1,12)} = 2.6$, $p = 0.12$
340 for interaction.

341

342 We calculated an “activation index” (AI), defined by the ratio between the summed spectral power
343 in the beta and low-gamma bands and the delta band power, to quantify alterations in spectral balance
344 between high- and low-frequency power components, similarly to what has been done previously in
345 studies on insomnia disorders (Lecci et al., 2020). The AI is a measure for the degree of EEG
346 desynchronization and increases when NREMS moves closer to wakefulness. In the fragility periods
347 continuing into NREMS and devoid of EMG activity, the AI decreased, consistent with NREMS remaining
348 consolidated (**Figure 5A-C**). In SNI animals, however, the AI was higher compared to Sham specifically in
349 the fragility periods (**Figure 5B**, mixed-model ANOVA with factors ‘treatment’ and ‘period’, $p = 0.039$ for
350 interaction, *post-hoc t*-tests Sham vs SNI in fragility period, $p = 0.005$, in continuity period, $p = 0.027$, not

351 significant with $\alpha = 0.0125$). Fragility periods during uninterrupted NREMS are thus specific moments
352 during which the AI in SNI conditions was significantly higher compared to continuity periods.

353 Can such mean differences in cortical activation profiles during NREMS qualify as differences in
354 cortical arousals? To address this, we compared the AI in fragility periods *with* a MA (associated with EMG
355 increase). As expected, the AI showed an intermittent phasic peak (**Figure 5D-F**) in most cases (75.2 ± 4.1
356 %), which is explained by the strong decline in delta power (see **Figure 2C**) and the appearance of higher
357 frequencies associated with MAs. Therefore, we inspected individual fragility periods continuing into
358 NREMS (without a MA) for the presence of similar phasic increases in AI. Indeed, we noticed that a subset
359 of these did indeed contain an intermittent peak resembling the one found during MAs (**Figure 5G**) and
360 not evident in the mean AI in **Figure 5B**. The amplitudes of these peaks were higher in SNI, in accordance
361 with the tonically higher AI in these animals, but in size comparable to the ones of MAs (**Figure 5H**, mixed-
362 model ANOVA with factors ‘treatment’ and ‘MA’, $p = 0.002$ for ‘treatment’, $p = 2.1 \times 10^{-7}$ for ‘MA’, no
363 interaction). Moreover, the half-widths of these peaks were only moderately smaller than the ones of
364 MAs (**Figure 5I**, mixed-model ANOVA with factors ‘treatment’ and ‘MA’, $p = 0.62$ for ‘treatment’, $p =$
365 3.28×10^{-7} for ‘MA’, no interaction). These events could thus qualify as a local cortical arousal based on
366 phasic spectral properties reminiscent of a MA. To further support our assumption that these AI peaks
367 constituted arousals, we looked at heart rate increases known to accompany cortical arousals in human
368 (Sforza *et al.*, 2000; Azarbarzin *et al.*, 2014). The heart rate was distinctly higher during the fragility period
369 for cycles containing an AI peak as opposed to the ones without such peak (**Figure 5J**, mixed-model ANOVA
370 with factors ‘treatment’, ‘period’ and ‘peak’, $p = 0.007$ for the ‘peak’ x ‘period’ interaction). These events
371 were more frequent in SNI animals and followed a similar time-of-day dependence as the classical MAs
372 (**Figure 5K,L**, *t*-test Sham vs SNI, $p = 0.02$). Moreover, their increased occurrence was specific for S1HL
373 while absent in PrL and in the contralateral EEG (**Figure 5 – figure supplement 2**). The presence of a
374 subgroup of fragility periods continuing into NREMS, yet showing a cortical arousal, is noteworthy for
375 several reasons. First, it demonstrates that rodent NREMS shows local cortical intrusion of wake-related
376 activity in the absence of muscular activity. Second, these local cortical arousals in SNI showed
377 intermittent peaks in AI that were close the ones of MAs, indicating comparable cortical
378 desynchronization at the local level. Third, they were accompanied by heart rate increases that are
379 sensitive hallmarks of arousal in human (Azarbarzin *et al.*, 2014). Fourth, neuropathic pain goes along with
380 a specific increase in the relative occurrence of fragility periods with such AI peaks specifically in the S1HL
381 area. The systematic classification of fragility periods helped unravel these novel cortico-autonomic
382 arousals and their similarity to MAs. Still, other arousal-like events outside fragility periods could exist.



383

384 **Figure 5** – Mice generate local cortical arousals during NREMS that appear more frequently in SNI. (A)
 385 Normalized dynamics of sigma (10–15 Hz) and activation indices (calculated as $\ln((\beta + \text{low-}\gamma))$)


386 /delta)). Hypnogram is shown below. Shaded areas show cycles of the 0.02 Hz-fluctuation continuing into
387 NREMS. **(B)** Activation indices for cycles continuing into NREMS, with mean values shown in boxplots for
388 continuity (270—90°) and fragility periods (90—270°). Mixed-model ANOVA $F_{(1,12)} = 8.9$, $p = 0.011$ for
389 ‘treatment’; $F_{(1,12)} = 470.6$, $p = 5.4 \times 10^{-11}$ for ‘period’; $F_{(1,12)} = 5.33$, $p = 0.039$ for interaction. *Post-hoc t*-test
390 for Sham vs SNI in continuity: $t_{(12)} = -2.51$, $p = 0.027$; fragility: $t_{(12)} = -3.44$, $p = 0.005$; and across periods for
391 Sham: $t_{(4)} = 17.98$, $p = 5.6 \times 10^{-5}$; SNI: $t_{(8)} = 14.86$, $p = 4.1 \times 10^{-7}$; $\alpha = 0.0125$. **(C)** Corresponding EMG values
392 (normalized to the mean value in NREMS). Mixed-model ANOVA $F_{(1,12)} = 0.2$, $p = 0.65$ for ‘treatment’; $F_{(1,12)}$
393 $= 3.83$, $p = 0.07$ for ‘period’; $F_{(1,12)} = 1.31$, $p = 0.27$ for interaction. **(D-F)** Same presentation as in panels A-
394 C, for cycles of the 0.02 Hz-fluctuation associated with MAs. Shaded areas in panel D show cycles of the
395 0.02 Hz-fluctuation interrupted by a MA. Arrowhead in E denotes the peak of the intermittent increase in
396 AI due to MA occurrence. Statistics for E: Mixed-model ANOVA $F_{(1,12)} = 11.26$, $p = 0.0057$ for ‘treatment’;
397 $F_{(1,12)} = 25.34$, $p = 2.9 \times 10^{-4}$ for ‘period’; $F_{(1,12)} = 2.61$, $p = 0.13$ for interaction. Statistics for F: Mixed-model
398 ANOVA $F_{(1,12)} = 0.045$, $p = 0.83$ for ‘treatment’; $F_{(1,12)} = 44.5$, $p = 2.3 \times 10^{-5}$ for ‘period’; $F_{(1,12)} = 0.91$, $p = 0.35$
399 for interaction. **(G)** Six individual cases in one sham animal illustrating sigma (red) and AI (blue) dynamics
400 in uninterrupted cycles of the 0.02 Hz-fluctuation. Thick portions of the blue traces represent the AI during
401 the fragility period. Top three examples show an AI without an intermittent peak, bottom three examples
402 show an AI with a peak (Peak is denoted by green arrowheads and duration at half-maximum by the green
403 line). The horizontal line (mean AI per cycle) represents the threshold for peak detection. **(H)** Values of AI
404 at the intermittent peak for cycles with (left, MA) and without (right, NREMS) an interruption by a MA.
405 Mixed-model ANOVA $F_{(1,12)} = 14.94$, $p = 0.0022$ for ‘treatment’; $F_{(1,12)} = 110.29$, $p = 2.1 \times 10^{-7}$ for ‘MA’; $F_{(1,12)}$
406 $= 0.76$, $p = 0.39$ for interaction. **(I)** Duration of the intermittent peak at half-maximum, for cycles with (left,
407 MA) and without (right, NREMS) an interruption by a MA. Mixed-model ANOVA $F_{(1,12)} = 0.24$, $p = 0.62$ for
408 ‘treatment’; $F_{(1,12)} = 101.64$, $p = 3.28 \times 10^{-7}$ for ‘MA’; $F_{(1,12)} = 1.39$, $p = 0.26$ for interaction. **(J)** Left: Heart rate
409 dynamics (compared to the mean heart rate in NREMS), for cycles continuing into NREMS. Cycles are
410 divided in whether a peak in activation index (AI) was present (top) or not (bottom). Right: boxplot
411 quantification of the heart rate values shown on the left for continuity (270—90°) and fragility periods
412 (90—270°), for Sham and SNI in NREMS fragility periods without (left of the dotted line) or with (right of
413 the dotted line) an AI peak. Mixed-model three-way ANOVA $F_{(1,12)} = 1.75$, $p = 0.21$ for ‘treatment’; $F_{(1,12)} =$
414 26.71 , $p = 2.3 \times 10^{-4}$ for ‘peak’; $F_{(1,12)} = 11.18$, $p = 0.005$ for ‘period’; only significant interaction in ‘peak’ x
415 ‘period’ $F_{(1,12)} = 10.7$; $p = 0.007$. *Post-hoc* cycles with AI peak vs cycles without AI peak for sham in
416 continuity: $t_{(4)} = -4.01$, $p = 0.015$; Sham in fragility: $t_{(4)} = -4.61$, $p = 0.009$; SNI in continuity: $t_{(8)} = -2.82$, $p =$
417 0.022 ; SNI in fragility: $t_{(8)} = -3.51$, $p = 0.008$; $\alpha = 0.0125$. **(K)** Occurrence of fragility periods with intermittent
418 peak in AI across the light phase, quantified in boxplots on the right (unpaired *t*-test for Sham vs SNI $t_{(12)}$
419 $= -2.66$, $p = 0.02$). **(L)** Two level-pie plots for Sham (left) and SNI (right) representing the proportion of
420 cycles containing a MA or continuing in NREMS. These latter fragility periods are further subdivided into
421 the ones with intermittent peak (‘Peak’) and without intermittent peak (‘No peak’). The arrows show the
422 proportions for Sham (green) and SNI (yellow).

423

424 **The 0.02 Hz-fluctuation allows to anticipate elevated spontaneous arousability during NREMS**

425 We finally examined sensory arousability in SNI conditions, focusing on the somatosensory
426 modality. To anticipate fragility and continuity periods in real-time in the sleeping animal, we trained a
427 machine learning software to predict online periods of continuity and fragility based on EEG/EMG

428 recordings (**Figure 6A-E**). For the training, we used online-calculated 0.02 Hz-fluctuation estimates onto
429 which fragility and continuity periods were labelled using peak-and-trough detection of sigma power
430 dynamics (**Figure 6 – figure supplement 3**). To control for the accuracy of the online prediction, we visually
431 scored MAs in 12 C57Bl/6J animals implanted only for polysomnography and verified their position in
432 either online detected peak-to-trough ('online fragility') or trough-to-peak phases ('online continuity')
433 (**Figure 6F**). We compared the online prediction to that generated by chance through randomly shuffling
434 both online fragility and continuity point positions in the recordings. This showed that the MA proportions
435 obtained with the real detection exceeded those obtained by chance prediction (**Figure 6G**, for online
436 fragility periods, $p = 0.0004$, for online continuity periods, $p = 0.0028$). Online detection of peak-to-trough
437 and trough-to-peak periods of the 0.02 Hz-fluctuation is thus a versatile method to probe variations of
438 evoked arousability from NREMS.



439


440 **Figure 6** – On-line detection of fragility periods during mouse NREMS. **(A-E)** Input and output parameters
 441 for machine-learning of NREMS fragility and continuity periods. From the EEG and EMG up to the
 442 momentary time. **(A)** 4 last second of EEG and EMG at momentary time. **(B)** Ratio delta (1–4 Hz) over
 443 theta (5–10 Hz) from the FFT every s **(C)** normalized EMG levels. Together **(B,C)**, are the variables for state
 444 decision using appropriate thresholds (dashed lines, see Methods). **(D)** The 0.02 Hz-fluctuation was
 445 estimated (black line) from sigma values (red) every s. The black line was constructed using the last point
 446 of a 9th order polynomial fit over the last 200 s of sigma power values. **(E)** The network was trained to use
 447 the last 200 s of online 0.02 Hz-fluctuation and the present window of EEG and EMG to determine whether
 448 the animal was in continuity or in fragility. The detection was carried out only when the animal was likely
 449 in NREMS. **(F)** Representative trace resulting from an online detection of fragility and continuity periods
 450 over a period of NREMS. Every s of detection is marked by a dark or light grey circle for online continuity
 451 and fragility periods, respectively. The hypnogram below represents the visual scoring done offline, blind
 452 to the online detection. The offline-detected MAs are indicated by open circles over the corresponding
 453 point of online detection. **(G)** Left, Proportion of MAs scored during online detected fragility. Right,
 454 proportion of MAs scored over online detected continuity, for 13 animals (blue dots). Horizontal

455 histograms represent the distribution of possible values of these proportions for randomly shuffled points
456 of fragility or continuity. The mean proportions for the 13 animals fell at percentile 99.96 % for fragility
457 and 0.28 % for continuity.

458

459 **SNI conditions produce elevated somatosensory-evoked arousability from NREMS**

460 Evoked arousability was probed through applying sensory stimuli either during online detected
461 fragility or continuity periods. To deliver somatosensory stimuli remotely while the animals were asleep,
462 we attached vibrational motors to their head implant that could be triggered to briefly vibrate (for 3 s) to
463 test the chance for wake-up (**Figure 7A**). These motors were calibrated to vibrate with the same low
464 intensity (~ 30% of full power) across animals (**Figure 7 – figure supplement 4**). Vibrations were applied
465 randomly with 25% probability during either online detected fragility or continuity periods, for at least
466 two complete light phases per condition (**Figure 7B**). Intensity was chosen such that Sham animals showed
467 approximately equal chances for wake-up or sleep-through in online continuity periods (**Figure 7C**).
468 Moreover, these vibrations produced wake-ups that were short, indicating that the sleeping animal felt
469 only mildly perturbed. Consistent with prior findings, similar stimuli applied during online fragility periods
470 showed consistently higher chances for wake-up (Lecci et al., 2017). In SNI, sensory arousability was
471 elevated for both continuity and fragility periods, leading to highest values during the online fragility
472 periods (**Figure 7D**, mixed-model ANOVA with factors ‘treatment’ and ‘online period’, $p = 0.0049$ for
473 ‘treatment’, $p = 1.31 \times 10^{-8}$ for ‘online period’, no interaction). Interestingly, consistent with the tonic
474 increase in AI, this increase in sensory arousability in SNI was present across the whole light phase with a
475 conserved time of day dependence (**Figure 7E**).



476

477 **Figure 7** – Closed-loop probing of sensory-evoked arousability reveals a more fragile sleep in SNI. **(A)** Setup
 478 for delivering vibrating stimuli to the sleeping animal. A small vibrating motor was fixed at the end of the
 479 recording cable that was connected to the animal's headstage. When the algorithm presented in Figure 6
 480 detected a change to an online fragility or continuity for > 4 s, a 3-s mild vibration (see Methods) was
 481 delivered with a chance of 25%. **(B)** Example of NREMS periods with vibrations over online continuity (top)
 482 or fragility (bottom) periods. Dark and light circles represent the online detection (see Figure 6F). Vertical
 483 lines represent the moments when the vibrations were delivered. Color-codes for wake-up or sleep-
 484 throughs. **(C)** Representative EEG/EMG recordings representing a wake-up (top) and a sleep-through
 485 (bottom). Time of stimulus delivery is shaded. The artifacts caused by the vibrations were not considered
 486 during automated wake-up or sleep-through detection (see Methods). **(D)** Chances to wake-up in
 487 response to a vibration in online continuity (C) or online fragility (F) periods. Mixed-model ANOVA $F_{(1,14)} =$
 488 11.07, $p = 0.0049$ for 'treatment'; $F_{(1,14)} = 136.58$, $p = 1.31 \times 10^{-8}$ for 'period'; $F_{(1,14)} = 0.3$, $p = 0.58$ for
 489 interaction. **(E)** Probability of wake-up (pooled continuity and fragility) for Sham and SNI over the light
 490 phase (ZT0-12). Shaded areas are SEMs.

491 Discussion

492 Chronic pain is a widespread and complex condition compromising sleep. As poor sleep further
493 aggravates pain, therapeutic approaches to improve sleep quality have potential to attenuate disease
494 progression. Here, in efforts to tease apart pain-sleep associations, we decided to focus on mechanisms
495 of sleep disruptions at early stages of chronic pain. This study progresses on the sleep-pain association in
496 four essential ways. First, we show that brain and autonomic signatures of pain states during the day
497 intrude in a persistent manner into sleep in early phases of the disease. Second, sleep appeared
498 nevertheless preserved in architecture, in dominant spectral band power, and in homeostatic regulation.
499 Third, a previously undescribed spontaneous arousal during NREMS, showing local cortical activation with
500 concomitant heart rate increases, appeared more frequently in SNI conditions. Fourth, we also
501 demonstrate that fine mechanovibrational stimuli triggered brief wake-ups from NREMS more easily in
502 SNI animals. In summary, chronic pain impacts on NREMS in terms of arousability, more specifically in the
503 probability that NREMS transits towards diverse levels of wakefulness, either spontaneously, or with
504 external stimuli. Chronic pain additionally instates a tonic regional elevation of high-frequency electrical
505 activity. Both these consequences are not detectable in conventional measures of sleep. However, they
506 bear resemblance to pathophysiological markers of insomnia disorders and, as we show here, produce
507 elevated responsiveness to fine vibrational stimuli. The study further suggests that, amongst the many
508 peripheral and central circuit alterations caused by chronic pain, the ones affecting the primary
509 nociceptive sensory areas could serve as a site of entry to treat pain-related sleep disturbances directly at
510 early states of the disease. For example, targeted interference by transcranial stimulation techniques has
511 been proposed to modulate pain-related oscillations and could thus be probed to modify abnormal
512 arousals (Shirvalkar *et al.*, 2018; Hohn *et al.*, 2019).

513 The quantification and classification of arousals from NREMS, both in terms of their physiological
514 correlates and in their intensity, is central to estimate the severity of a sleep disorder. The fragmentation
515 of sleep by arousals is the primary cause for daytime fatigue and for cognitive deficits and, in more severe
516 cases, may constitute long-term risks for cardiovascular health (Bonnet *et al.*, 1992; Silvani, 2019). Criteria
517 for arousal scoring in humans are comparatively well established and there are strong indications that
518 arousal intensity is graded, with EEG desynchronization and concomitant heart rate acceleration occurring
519 independently of muscular activity (e.g. leg movements) (Sforza *et al.*, 2000; Azarbarzin *et al.*, 2014). In
520 chronic pain patients, few systematic analyses on spontaneous arousals are currently available and a need
521 for more polysomnographic assessments in well-controlled patient populations has been highlighted

522 (Bjurstrom & Irwin, 2016). In rodents, only few studies have described cortical desynchronization events
523 without EMG activity, and these were not characterized with respect to autonomic correlates (Bergmann
524 *et al.*, 1987; Franken, 2002; Léna *et al.*, 2004; Fulda, 2011). This relative lack of arousal characterization in
525 mouse NREMS could have hampered the identification of models to replicate sleep disorders, as we found
526 here to be the case for chronic pain models. To the best of our knowledge, our analysis of the SNI mouse
527 is the first that qualifies as a rodent model replicating physiological correlates of insomnia disorders that
528 are hidden behind a comparatively normal sleep and that could raise awareness for refined analysis of the
529 diverse forms of sleep disruptions in chronic pain patients (Bjurstrom & Irwin, 2016). Our work also adds
530 a novel variant to proposed insomnia models that provoked severe macroscopic sleep disruptions either
531 through acute stress (Cano *et al.*, 2008; Li *et al.*, 2020) or by optogenetically enforced full awakenings to
532 fragment NREMS (Rolls *et al.*, 2011).

533 This study proposes a novel type of arousal from NREMS in mouse that pairs cortical
534 desynchronization with heart rate increases. Inclusion of this type of arousal is crucial to identify the exact
535 sleep disruptions for the case of neuropathic pain. We departed here from previous observations on
536 infraslow variations in sensory arousability during NREMS that take place over the minute time-scale
537 (Lecci *et al.*, 2017). We first demonstrated that spontaneous MAs, the only spontaneous arousal in rodent
538 for which scoring criteria are widely established, occur remarkably clustered at phases for which sensory
539 evoked arousals were most likely (Lecci *et al.*, 2017). The high number of MAs and their remarkable
540 clustering at phases $> 90^\circ$ and $< 270^\circ$, allowed us to allocate the fragility periods to the phases with low
541 sigma power. We consider this basic finding on MA timing in rodent NREMS significant for several reasons.
542 First, it suggests that the infraslow 0.02 Hz-fluctuation is part of an overarching process that periodically
543 sets a fragility of NREMS towards wake-promoting inputs, whether they arise from internal processes or
544 external stimuli. Mechanistically, this points to an involvement of widely projecting neuromodulatory
545 brain areas such as the locus coeruleus that remains active during NREMS (Aston-Jones & Bloom, 1981;
546 Kjaerby *et al.*, 2020) and regulates sensory arousability (Hayat *et al.*, 2020). Second, the finding contributes
547 to a long-standing uncertainty about the origin and the stochastic time-scales on which MAs are thought
548 to occur (Lo *et al.*, 2004; Dvir *et al.*, 2018). We now calculate that MAs in consolidated NREMS occur with
549 a mean $\sim 35\%$ probability on ~ 50 -sec intervals, thus providing a temporal raster on which these can be
550 anticipated with a measurable degree of certainty. MAs depend on activity in wake-promoting brain areas
551 (Dvir *et al.*, 2018), specifically on the histaminergic hypothalamus in mice (Huang *et al.*, 2006) and on
552 cholinergic nicotinic receptors (Léna *et al.*, 2004). This mechanistic origin of MAs is consistent with our
553 observation that they occur at moments of NREMS during which sensory wake-ups occur preferentially.

554 We therefore consider the identification of fragility periods as time raster for MAs as key to reinforce
555 mechanistic investigations into the origins of spontaneous arousals. This not only concerns MAs, but
556 opens the opportunity to search for other arousal-like events that could be relevant to model pathological
557 conditions of human patients.

558 The majority of this study was dedicated to providing a proof-of-concept for the usefulness of the
559 infraslow fragility periods to scrutinize arousability. The chosen SNI model appeared particularly
560 appropriate for this purpose because it produced a sensory deficit that could be exploited to specifically
561 test somatosensory arousability. The separation of NREMS into fragility and continuity periods throughout
562 the resting phase allowed us to sample and scrutinize the many fragility periods continuing apparently
563 uninterrupted into NREMS. The fragility periods were also critical to determine when AI became most
564 disparate between SNI and Sham and to identify previously undescribed cortico-autonomic arousals.
565 During these, the activation index increased because of a phasic decrease in low-frequency delta power
566 and an increase in high-frequency power. These events were more pronounced and more frequent in SNI
567 because both these phasic power alterations were disrupted, with the deficits in delta power most
568 pronounced. Without the raster provided by the fragility periods, the phasic differences amidst the
569 tonically elevated high-frequency power would easily have gone undetected. To further ascertain that
570 these detected events nevertheless constituted true arousals rather than accidental spectral fluctuations,
571 we sought for independent physiological correlates. Inspired by the human literature (Sforza et al., 2000;
572 Azarbarzin et al., 2014), we found that heart rate increases were consistently higher when calculated for
573 cortical arousals with AI peak than for the ones without AI peak. Moreover, their distribution across the
574 resting phase was similar to the one found for MAs and they were present in both S1HL and PrL. This
575 result supports our interpretation that we have identified here a novel cortical-autonomic arousal subject
576 to similar time-of-day-dependent regulatory mechanisms. Still, we cannot exclude that arousal subtypes
577 outside the fragility periods went undetected that would require further characterization. We also remark
578 here clearly that, aside from more frequent cortico-autonomic arousals, SNI animals suffered from a
579 tonically elevated high-frequency power in S1HL that likely underlay the more elevated sensory
580 arousability throughout continuity and fragility periods.

581 The lack of major sleep disruptions in the SNI mouse model was initially unexpected but seemed in
582 line with other studies. We analyzed these animals at a time point when pain from the wound and
583 associated inflammations are largely over (Guida *et al.*, 2020), both of which can strongly disrupt sleep
584 (Landis *et al.*, 1989; Andersen & Tufik, 2003; Silva *et al.*, 2008). Moreover, the animals showed a preserved
585 time spent in REMS, suggesting that they did not suffer from chronic mild stress-inflicted sleep disruptions

586 (Nollet *et al.*, 2019). Other studies on chronic pain also report diverse moderate effects on sleep (Kontinen
587 *et al.*, 2003; Leys *et al.*, 2013). One study on rats at 2 and 10 days after SNI surgery suggested that brain
588 states intermediate between NREMS and wakefulness during the resting phase exist (Cardoso-Cruz *et al.*,
589 2011), which could in part reflect our observations. We also found no alterations in theta power or for
590 shifts in theta peaks in wakefulness, as reported for other animal models of chronic pain (LeBlanc *et al.*,
591 2014) or for humans with severe neurogenic pain or arthritis (Sarnthein *et al.*, 2006). Analysis of sleep
592 disruptions at later stages in the disease will help decide whether distinct phases of sleep disruptions mark
593 distinct phases of pain chronicity when anxiety- and depression-related behaviors appear more strongly
594 (Guida *et al.*, 2020).

595 The spectral dynamics in two cortical regions we present here delineate possible areas of
596 pathological neuronal activity that underlie the cortical arousals. The continued presence of high-
597 frequency activity in S1HL is reminiscent of the cortical oscillatory activity evoked with acute painful
598 stimuli, suggesting that nociceptive input continues to arrive in cortex during NREMS to generate
599 excessive excitation. Indeed, it has been suggested that the SNI model does show spontaneous ectopic
600 electrical activity in peripheral sensory neurons as a result of nerve injury (Wall & Devor, 1983; Devor,
601 2009). NREMS is thought to protect relatively weakly from nociceptive inputs (Claude *et al.*, 2015),
602 therefore possibly allowing continued processing of spontaneous nociceptive activity that could explain
603 the cortical spectral changes we detected. It has also been shown that optogenetic stimulation of the
604 thalamic reticular nucleus, known to be implied in the balanced occurrence of delta and spindle waves
605 during NREMS (Fernandez *et al.*, 2018), can alleviate pain in SNI (LeBlanc *et al.*, 2014). Suppressed TRN
606 activity during NREMS could be implied in the attenuated delta dynamics observed in NREMS of SNI mice.
607 In contrast, we found unperturbed local spectral dynamics in PrL during NREMS, although this area is
608 concerned with signaling emotional discomfort in several forms of chronic pain in humans (Schulz *et al.*,
609 2015; Nickel *et al.*, 2017; May *et al.*, 2019) and is known to undergo strengthened synaptic inhibition in
610 SNI (Zhang *et al.*, 2015; Radzicki *et al.*, 2017). Further cellular studies will be necessary to understand why
611 these alterations seem not to perturb oscillatory activity in this area during NREMS.

612 Do SNI animals suffer from insomnia? Our objective measures of NREMS's spectral composition
613 point to regionally restricted but tonic imbalances in the contribution of low- vs higher frequencies.
614 Patients with insomnia show such imbalances over widespread brain regions that include sensorimotor
615 areas (Lecci *et al.*, 2020). Furthermore, higher power in the beta frequencies has been related to the
616 patients remaining hypervigilant or excessively ruminating at sleep onset (Perlis *et al.*, 2001a), preventing
617 the deactivation of cortical processes required for the loss of consciousness. Although insomnia also needs

618 subjective assessments that are not possible in animals, this phenomenological comparison suggests that
619 SNI might suffer from similar experiences due to the tonically enhanced high-frequency oscillations. This
620 interpretation is supported by the elevated wake-up rates in response to mild vibrational stimuli
621 throughout the infraslow cycles, suggesting hyperalertness to environmental disturbance. On top of these
622 tonic changes, there were more frequent cortico-autonomic arousals. Although these do not seem to
623 elevate daytime sleepiness based on the mostly unchanged delta power dynamics across time-of-day,
624 frequent increases in heart rate during the night could augment cardiovascular risk in the long-term
625 (Silvani, 2019). To further analyze the animal's conditions during daytime, tests on their cognitive abilities
626 in memory-dependent tasks while locally manipulating sleep in the affected hindlimb area could be
627 considered. Deficits in working and declarative memories in rodents with SNI have been documented from
628 early periods of chronic pain (Guida et al., 2020). Chemogenetic manipulation of neuronal populations
629 proposed to be responsible for the gamma activity in chronic pain, restricted to sleep periods (Tan et al.,
630 2019), seems a feasible approach to specifically suppress abnormal pain-related activity during sleep while
631 testing performance in such tasks during wakefulness.

632 We provide here novel approaches to classify arousals in mouse NREMS that will help in the
633 examination and validation of future candidates for rodent models of sleep disorders. We noted a
634 remarkable stability of the 0.02 Hz-fluctuation across the resting phase that provided us with a temporal
635 raster to screen the characteristics of fragility periods. These led us to identify a previously undescribed
636 cortico-autonomic arousal in mouse NREMS that we also found more frequently in a chronic pain model.
637 Together, this study presents NREMS as a state that is interwoven with arousals showing diverse
638 combinations of physiological parameters with different graduations in intensity that can be the target of
639 pathophysiological changes. Recognizing NREMS as a fluctuating state between fragility and continuity
640 will thus further heighten awareness to arousability as a core component of sleep quality. In this study,
641 we unraveled a so far undescribed sleep disruption in chronic pain that we hope will facilitate further
642 research into the treatment of this devastating condition.

643

644 Materials and methods

645 **Animal housing and experimental groups**

646 Mice from the C57BL/6J line were singly housed in a temperature- and humidity-controlled environment
647 with a 12-h/12 h light-dark cycle (lights on at 9:00 am, corresponding to ZT0), with access to food and
648 water *ad libitum*. We first used 36 mice, 10-14 weeks-old and bred in our colonies in a conventional-clean

649 animal house, for polysomnography (combined EEG (ECoG)/EMG electrodes), followed by SNI or Sham
650 surgery (18 animals per Sham or SNI group). Mice were transferred from the animal house into the
651 recording room 2-3 d before surgery for polysomnography recording. We recorded a 48 h-long baseline
652 before SNI or Sham surgeries, followed by recording at 22-23 d after surgery (D20+). These data were used
653 for Figures 1 and 3. Total sleep deprivation in Figure 3 was done on 24 of these 36 animals (12 SNI, 12
654 Sham) within one day following the recording at D20+. The baseline data for Figure 2 were obtained from
655 the baseline recordings of 23 randomly selected animals from the previous 36, completed with 7 more
656 animals from previous baseline recording in the lab. For EEG (ECoG)/EMG/LFP recordings, 33 C57BL/6J
657 male mice of the same age were first operated for SNI or Sham (17 and 14, respectively) and 5 d later,
658 implanted for recordings from S1HL (4 Sham, 6 SNI) or PrL (3 Sham, 4 SNI) or both (3 Sham, 4 SNI). The
659 misplaced or non-functional electrodes were excluded. Recordings were carried on from day 20 to 35
660 after SNI or Sham surgery. These data were used for Figures 4 and 5. The data of 13 animals previously
661 recorded in the lab and otherwise not included in any dataset in this study were used to train the neural
662 network (EEG/EMG implantation, in *Figure 6*). The experiments on sensory evoked arousals (*Figure 7*)
663 were done on 16 animals (8 Sham, 8 SNI) out of which some (4 sham, 6 SNI) were used for Figures 4-5. All
664 experimental procedures complied with the Swiss National Institutional Guidelines on Animal
665 Experimentation and were approved by the Swiss Cantonal Veterinary Office Committee for Animal
666 Experimentation.

667 **Surgery for the SNI model of neuropathic pain**

668 The Sham and SNI surgeries were performed as previously described (Decosterd & Woolf, 2000). Briefly,
669 mice were kept under gas anesthesia (1–2 % isoflurane, mixed with O₂). The left hindleg was shaved
670 and the skin incised. The muscles were minimally cut until the sciatic nerve was exposed. Just below the
671 trifurcation between common peroneal, tibial and sural branches of the nerve, the common peroneal and
672 tibial branches were ligated and transected. The Sham animals, as controls, went through the same
673 surgery without the transection. The muscle and the skin were then stitched closed and the animals were
674 monitored via a score sheet established with the Veterinarian Authorities.

675 **Surgery for polysomnographic and LFP recordings in mice**

676 Surgeries were performed as recently described (Lecci et al., 2017; Fernandez et al., 2018). Animals were
677 maintained under gas anesthesia (1–2 % isoflurane, mixed with O₂). Small craniotomies were performed
678 in frontal and parietal areas over the right hemisphere and 2 gold-plated screws (1.1 mm diameter at their

679 base) (Mang & Franken, 2012) were gently inserted to serve as EEG electrodes. Careful scratching of the
680 skull surface with a blade strengthened the attachment of the implant by the glue, so that additional
681 stabilization screws were no longer necessary. Two gold wires were inserted into the neck muscle to serve
682 as EMG electrodes. In the case of LFP recordings, small craniotomies (0.2-0.3 mm) were performed to
683 implant high-impedance tungsten LFP microelectrodes (10–12 M Ω , 75- μ m shaft diameter, FHC, Bowdoin,
684 ME) at the following stereotaxic coordinates relative to Bregma in mm, for S1HL: anteroposterior -0.7,
685 lateral -1.8, depth from surface -0.45; for PrL : +1.8, -0.3, -1.45). For the neutral reference for the LFP
686 recordings, a silver wire (Harvard Apparatus, Holliston, MA) was placed in contact with the bone within a
687 small groove drilled above the cerebellum. The electrodes were then soldered to a female connector and
688 the whole implant was covered with glue and dental cement. The animals were allowed 5 d of recovery,
689 while being monitored via a score sheet established with the Veterinarian Authorities, with access to
690 paracetamol (2mg/mL, drinking water). The paracetamol was removed when the animals were tethered
691 to the recording cable for another 5 d of habituation prior to the recording.

692 **Polysomnographic recording**

693 For sleep recordings, recording cables were connected to amplifier boards that were in turn connected to
694 a RHD USB interface board (C3100) using SPI cables (RHD recording system, Intan Technologies, Los
695 Angeles, CA). For EEG/EMG and/or LFP electrodes, signals were recorded through homemade adapters
696 connected to RHD2216 16-channel amplifier chips with bipolar input or RHD2132 32-channel amplifier
697 chips with unipolar inputs and common reference, respectively. Data were acquired at 1000 Hz via a
698 homemade Matlab recording software using the Intan Matlab toolbox. Each recording was then visually
699 scored in 4-s epochs into wake, NREMS, REMS, as described (Lecci et al., 2017) using a homemade Matlab
700 scoring software.

701 **Total sleep deprivation protocol**

702 Total SD was carried out from ZT0—ZT6 using the gentle handling method used previously in the lab (Kopp
703 et al., 2006), while animals remained tethered in their home cage. At ZT3, the cages were changed and,
704 from ZT5 to ZT6, new bedding material was provided. At ZT6, the animals were left undisturbed. The
705 recordings carried out during SD were visually scored to assure the absence of NREMS from ZT0 to ZT6.
706 There were no detected NREMS epochs during SD in the mice included in the analysis.

707 **Probing sensory arousability with vibration motors and automatic wake-up classification**

708 An online detection of continuity and fragility period (described below) was used in a closed-loop manner
709 to time vibration stimuli during NREMS such that sensory arousability could be probed. Small vibrating
710 motors (DC 3—4.2 V Button Type Vibration Motor, diameter 11 mm, thickness 3 mm) were fixed using
711 double-sided tape, at the end of the recording cables, close to the animals' heads. The motors were driven
712 using a Raspberry Pi 3B+ through a 3.3 V pulse-width modulation (PWM) signal. Each motor was calibrated
713 to find the necessary PWM duty-cycle to output the same amount of mild vibration using a homemade
714 vibration measurer equipped with a piezo sensor. A Python script was running on the Raspberry Pi to
715 detect the voltage change sent by the digital-out channels on the Intan RHD USB interface board. Upon
716 detecting a change from low to high, the Python script waited for an additional 4 s, and assessed the
717 voltage again. In case the voltage was still high, it launched a 3 s vibration with 25% probability. To close
718 the loop, the PWM signals from the Raspberry Pi driving the motors were as well fed into the analog-in
719 channels of the Intan RHD USB interface board to detect the stimuli time-locked to the EEG/EMG signals.
720 In the experiments, the voltage values were set to high during either continuity or fragility, using online
721 detection as described in Data analysis. Four animals could be tested in parallel for their sensory
722 arousability.

723 **Histological verification of recording sites**

724 After the *in vivo* LFP recordings, the animals were deeply anesthetized with pentobarbital (80 mg/kg) and
725 electrode positions were marked through electro-coagulation (50 μ A, 8—10 s). The animals were then
726 transcardially perfused with 4 % paraformaldehyde (in 0.1 M phosphate buffer). After brain extraction
727 and post-fixation for 24 h, 100 μ m-thick coronal brain sections were cut and imaged in brightfield
728 microscopy to verify correct electrode positioning.

729 **Data analysis**

730 Scoring and basic sleep measures

731 Scoring was done blind to the animal treatment according to standard scoring procedures (Fernandez et
732 al., 2018). A MA was scored whenever the EEG presented a desynchronization time-matched with a burst
733 of EMG activity lasting maximally 4 consecutive epochs (16 s). Latency to sleep onset was defined from
734 ZT0 to the first appearance of 6 consecutive NREMS epochs (24 s). The bout size binning in short,
735 intermediate and long bouts for NREMS and REMS was obtained from the pulled distribution of the bout
736 sizes from all the animals. The edges of the intermediate bin were defined as: mean - $\frac{1}{2}$ standard deviation
737 to mean + 1 standard deviation.

738 Spectral power was computed on the raw EEG signal using a FFT on scored 4-s windows after offset
739 correction through subtraction of the mean value of each epoch. The median power spectrum for each
740 state was obtained for epochs non-adjacent to state transitions. The normalization was done through
741 dividing by the average of mean power levels (from 0.75–47 Hz) for each vigilance state, ensuring that
742 each state had the same weight in the averaging (Vassalli & Franken, 2017). This normalization was done
743 separately for Baseline and D20+ recordings. Gamma power at D20+ was extracted through calculating
744 mean power levels between 60–80 Hz. Data were normalized to corresponding baseline values.

745 The heart rate was extracted from the EMG signal as described previously (Lecci et al., 2017). Briefly, the
746 EMG signal was highpass-filtered (>25 Hz) and squared. The R peaks of the heartbeats were detected using
747 the Matlab 'Findpeaks' function. Only animals with clearly visible R peaks present in the EMG in NREMS
748 were included in this analysis (Fernandez *et al.*, 2017).

749 For delta power time course, raw delta power (mean power between 1–4 Hz from FFT on mean-centered
750 epochs) was extracted for each NREMS epoch non-adjacent to a state transition. Total NREMS time was
751 divided into periods of equal amounts of NREMS (12 in light phases, 6 in dark phases) from which mean
752 values for delta power were computed. The position in time of these periods was not different between
753 groups. Normalization was done via mean values between ZT9–12, when sleep pressure is the lowest.

754 Wake-up and sleep-through events after vibration were scored automatically as follows. For each trial,
755 the EEG and EMG signals were analyzed within time intervals from 5 s prior to 5 s after the vibrations. To
756 distinguish wake-up and sleep-through events, three values were calculated: 1) The ratio theta (5-10 Hz)/
757 delta (1-4 Hz) for the 5 s before stimulation, 2) the difference in the low- / high-frequency ratios (1-4 Hz/
758 100–500 Hz), before and after the stimulation, 3) the squared EMG amplitude ratio after/ before
759 stimulation.

760 A trial was rejected when the ratio theta/delta was > 1 before stimulation or the EMG amplitude was
761 larger before than after stimulation. In this way, trials starting in REMS or wakefulness were excluded.
762 Wake-up events were scored when the difference in low/high ratios mentioned above decreased
763 markedly after stimulation together with EMG activity. Occasionally, some wake-ups were also scored
764 when EEG or EMG activity was very high while the other channel showed moderate changes. Appropriate
765 thresholds were set upon visual inspection blinded to the animal's condition.

766 Analyses related to the 0.02 Hz-fluctuation

767 Extraction - The 0.02 Hz-fluctuation in sigma power (10–15 Hz) was extracted from EEG or LFP signals
768 using a wavelet transform (Morlet wavelet, 4 cycles), calculated over 12 h recordings in 0.5-Hz bins. The
769 resulting signal was down-sampled to 10 Hz and smoothed using an attenuating FIR filter (cutoff frequency
770 0.0125 Hz, order of 100, the low order allowing for frequencies above the cutoff). The mean of the
771 datapoints within NREMS and MA epochs was used for normalization (**Figure 2- figure supplement 1D**).
772 The peak and frequency of the 0.02 Hz-fluctuation were calculated through a FFT on continuous NREMS
773 bouts as described (Lecci et al., 2017). FFTs from individual bouts at frequency bins from 0 to 0.5 Hz were
774 interpolated to 201 points before averaging across bouts to obtain a single measure per mouse. The angles
775 of the phase of the 0.02 Hz-fluctuation were obtained through the Hilbert transform (Matlab signal
776 processing toolbox). We set the troughs of the 0.02 Hz-fluctuation at 180°, the peaks at 0° (**Figure 2- figure
777 supplement 1G**).

778 In several instances (**Figures 3D, 4, 5**), instead of calculating FFTs in the infraslow frequency range, we
779 needed to detect individual cycles of the 0.02 Hz-fluctuation. To do this, we applied the Matlab
780 “Findpeaks” function, with the conditions that the peak values were > mean and the trough values < mean,
781 each separated by > 20 s. With such parameters, the sequence trough-peak-trough appears only in NREMS
782 and allows to count individual cycles.

783 Band-limited power dynamics during the 0.02 Hz-fluctuation - To calculate the power dynamics in
784 different frequency bands, Morlet wavelet transforms were down-sampled to 10 Hz to match the
785 sampling of the 0.02 Hz-fluctuation and normalized by the sum of their means in NREMS. The mean power
786 of each band was then binned in 18 bins of 20° and a mean across cycles (with or without MAs) of power
787 activity per phase bin was obtained per animal.

788 Analysis of activation index - AI was computed by the natural logarithm (ln) of the ratio between beta (16–
789 25 Hz) + low gamma (26–40 Hz) over delta power (1–4 Hz), extracted as described above. Individual cycles
790 from peak-to-peak were classified whether a MA was present in the fragility period or whether it
791 continued into NREMS. To assess the presence of peaks in activation indices, the “findpeaks” function was
792 used at phase values of 90–270°, with mean values used as a threshold.

793 Online detection of continuity and fragility periods - For the online detection of fragility and continuity
794 periods during closed-loop sensory stimulation, a homemade software was generated with two layers of
795 decision. The first one determined the likely current state of vigilance (wake, NREMS or REMS), whereas
796 the second one made a machine learning-based decision between a continuity or a fragility period.

797 1 – Determination of vigilance state. This assessment was based on power band ratios characteristic for
798 wake, NREMS and REMS using appropriate thresholds (**Figure 6B,C**). Every s, a FFT was calculated on the
799 mean-centered last 4 s of EEG values and the power ratio between the delta (1–4 Hz) and the theta (5–
800 10 Hz) was calculated.

801 **Transitions out of wake:** 1) Switch to NREMS if the last 3 s of EMG were below a high threshold and at
802 least 2 out of the 3 last s of ratio were above a high threshold. 2) Switch to REMS if the full 5 s of EMG
803 were below a low threshold and the full 5 s of ratio were above a high threshold.

804 **Transitions out of NREMS:** 1) Switch to wake if the last s of EMG was above a high threshold. 2) Switch to
805 REMS if the last five s of EMG were below a low threshold and if among the last 5 s of ratio, at least 4 were
806 below a low threshold and all 5 were below a high threshold.

807 **Transitions out of REMS:** 1) Switch to wake if the last s of EMG were above a high threshold. 2) Switch to
808 NREMS if the ratio was above a high threshold for at least 4 out of 5 s.

809 2 – Continuity and fragility detection. From the previous step, the value of sigma (10–15 Hz) was kept
810 every second. The mean sigma value in NREMS was dynamically updated if the likely state was determined
811 as NREMS and used to normalize the incoming sigma power values. The last 200 s of sigma power
812 regardless of the likely state were kept in memory. We heuristically found that a 9th-order polynomial fit
813 (Matlab ‘polyfit’ and ‘polyval’ functions) best approximated the 0.02 Hz-fluctuation. To train the network,
814 we first generated online-estimated 0.02 Hz-fluctuation at 1 Hz for the 12 h of the light phase. We next
815 applied offline cycle detection in NREMS periods. For simplicity, and in agreement with previous measures
816 of sensory arousability (Lecci et al., 2017), we set the continuity periods from trough to peak and fragility
817 from peak to trough. Then, we subdivided these recordings in chunks of 200 s (moving window of 1 s, as
818 they would appear online) and keeping the label continuity, fragility or none for each of them. We could
819 thus obtain 43,000 labelled chunks per 12 h of recording. We used 642,000 of these chunks from 13
820 animals to train a neural network (pattern recognition ‘nprtool’ from Matlab Statistics and Machine
821 Learning Toolbox) 70 % of the for training, 15 % for validation and 15 % for testing. The network was
822 composed of one hidden layer with 10 neurons and one output layer with the 3 different output. We then
823 used the generated neural network online to take the decision between continuity, fragility or none.

824 **Statistics**

825 The statistics were done using Matlab R2018a and the R statistical language version 3.6.1. The normality
826 and homogeneity of the variances (homoscedasticity) were assessed using the Shapiro-Wilk and the

827 Bartlett tests, respectively to decide for parametric statistics. In the cases where normality or
828 homoscedasticity were violated, a log transformation was assessed at first and finally, non-parametric
829 *post-hoc* tests were used (Wilcoxon rank sum test for unpaired and signed-rank test for paired data). The
830 degrees of freedom and residuals for the F values are reported according to the R output. *Post-hoc*
831 analyses were done only when the interaction between factors were significant ($p < 0.05$). Bonferroni's
832 correction for multiple comparisons was applied routinely, and the corrected α values are given in the
833 legends. The factors used in the ANOVAs are depicted with pictograms once the corresponding effects
834 were significant. The factors used in the analysis were: 'treatment' with two levels: Sham and SNI; 'day'
835 with two repeated levels: baseline and D20+; 'size' with three repeated levels: small, intermediate or long
836 bouts; 'period' with two repeated levels: continuity or fragility; 'SD' with two repeated levels: control or
837 recovery after sleep deprivation; 'state' with three repeated levels: wake, NREMS or REMS; 'MAS' with
838 two levels: with or without MA in the fragility period; 'peak' with two repeated levels: cycles with or
839 without a peak in AI during fragility periods. The circular statistics were done using the CircStat for Matlab
840 toolbox (Berens, 2009).

841 Acknowledgements

842 All lab members provided critical input at all stages of this manuscript. The excellent animal caretaking
843 headed by Michelle Blom and the Team of Animaliers, in particular Titouan Tromme, is highly appreciated.
844 Expert veterinary support and advice was provided by Drs. Gisèle Ferrand and Laure Sériot. We thank
845 Christiane Devenoges for support in histological analysis and Marie Pertin and Guylène Kirschmann for
846 excellent technical support with SNI surgeries. Dr. Simone Astori and Dr. Marc Suter provided insightful
847 comments on pre-final versions of the manuscript and Laura Solanelles Farré helped with careful
848 proofreading. The useful discussions with Raquel Sandoval Adaia, Paul Franken, Thomas Nevian,
849 Francesca Siclari and Raphaëlle Winsky-Sommerer are gratefully acknowledged. This study was funded by
850 The Swiss National Science Foundation (n° 310030_184759 to AL, n° 310030_179169 to ID, n° 320030-
851 179194 to SF), and Etat de Vaud.

852 Competing interests

853 The authors declare no competing interests.

854

855

856 Author contributions

857 Romain Cardis, Conceptualization, Data collection, Data curation, Formal analysis, Software, Validation,
858 Investigation, Visualization, Methodology, Figures, Writing—review and editing; Sandro Lecci,
859 Conceptualization, Data collection, Data curation, Formal analysis, Methodology; Laura Fernandez,
860 Methodology, Data curation; Alejandro Osorio-Forero, Methodology; Paul Chu Sin Chung, Editing;
861 Stephany Fulda, Conceptualization, Data Validation, Writing—review and editing; Isabelle Decosterd and
862 Anita Lüthi, Conceptualization, Data curation, Supervision, Funding acquisition, Validation, Visualization,
863 Writing—original draft, Project administration, Writing—review and editing.

864 References

- 865 Alexandre, C., Latremoliere, A., Ferreira, A., Miracca, G., Yamamoto, M., Scammell, T. E., & Woolf, C. J.
866 (2017). Decreased alertness due to sleep loss increases pain sensitivity in mice. *Nat Med*, *23*(6),
867 768-774. doi: 10.1038/nm.4329
- 868 Andersen, M. L., & Tufik, S. (2003). Sleep patterns over 21-day period in rats with chronic constriction of
869 sciatic nerve. *Brain Res*, *984*(1-2), 84-92. doi: 10.1016/s0006-8993(03)03095-6
- 870 Aston-Jones, G., & Bloom, F. E. (1981). Norepinephrine-containing locus coeruleus neurons in behaving
871 rats exhibit pronounced responses to non-noxious environmental stimuli. *J Neurosci*, *1*(8), 887-
872 900.
- 873 Azarbarzin, A., Ostrowski, M., Hanly, P., & Younes, M. (2014). Relationship between arousal intensity
874 and heart rate response to arousal. *Sleep*, *37*(4), 645-653. doi: 10.5665/sleep.3560
- 875 Berens, P. (2009). CircStat: A MATLAB toolbox for circular statistics. *J Stat Software*, *31*(10), 1-21. doi:
876 10.18637/jss.v031.i10
- 877 Bergmann, B. M., Winter, J. B., Rosenberg, R. S., & Rechtschaffen, A. (1987). NREM sleep with low-
878 voltage EEG in the rat. *Sleep*, *10*(1), 1-11.
- 879 Bjurstrom, M. F., & Irwin, M. R. (2016). Polysomnographic characteristics in nonmalignant chronic pain
880 populations: A review of controlled studies. *Sleep Med Rev*, *26*, 74-86. doi:
881 10.1016/j.smr.2015.03.004
- 882 Bonnet, M., Carley, D., Carskadon, M., Easton, P., Guilleminault, C., Harper, R., Hayes, B., Hirshkowitz,
883 M., Ktonas, P., Keenan, S., Pressman, M., Roehrs, T., Smith, J., Walsh, J., Weber, S., &
884 Westbrook, P. (1992). The Atlas Task Force. EEG arousals: Scoring rules and examples. *Sleep*, *15*,
885 173-184.
- 886 Bourquin, A. F., Süveges, M., Pertin, M., Gilliard, N., Sardy, S., Davison, A. C., Spahn, D. R., & Décosterd, I.
887 (2006). Assessment and analysis of mechanical allodynia-like behavior induced by spared nerve
888 injury (SNI) in the mouse. *Pain*, *122*(1-2), 14 e11-14. doi: 10.1016/j.pain.2005.10.036
- 889 Burma, N. E., Leduc-Pessah, H., Fan, C. Y., & Trang, T. (2017). Animal models of chronic pain: Advances
890 and challenges for clinical translation. *J Neurosci Res*, *95*(6), 1242-1256. doi: 10.1002/jnr.23768
- 891 Buysse, D. J., Germain, A., Hall, M. L., Moul, D. E., Nofzinger, E. A., Begley, A., Ehlers, C. L., Thompson,
892 W., & Kupfer, D. J. (2008). EEG spectral analysis in primary insomnia: NREM period effects and
893 sex differences. *Sleep*, *31*(12), 1673-1682. doi: 10.1093/sleep/31.12.1673

- 894 Cano, G., Mochizuki, T., & Saper, C. B. (2008). Neural circuitry of stress-induced insomnia in rats. *J*
895 *Neurosci*, *28*(40), 10167-10184. doi: 10.1523/JNEUROSCI.1809-08.2008
- 896 Cardoso-Cruz, H., Sameshima, K., Lima, D., & Galhardo, V. (2011). Dynamics of circadian thalamocortical
897 flow of information during a peripheral neuropathic pain condition. *Front Integr Neurosci*, *5*, 43.
898 doi: 10.3389/fnint.2011.00043
- 899 Christensen, J. A. E., Wassing, R., Wei, Y., Ramautar, J. R., Lakbila-Kamal, O., Jennum, P. J., & Van
900 Someren, E. J. W. (2019). Data-driven analysis of EEG reveals concomitant superficial sleep
901 during deep sleep in insomnia disorder. *Front Neurosci*, *13*, 598. doi: 10.3389/fnins.2019.00598
- 902 Claude, L., Chouchou, F., Prados, G., Castro, M., De Blay, B., Perchet, C., Garcia-Larrea, L., Mazza, S., &
903 Bastuji, H. (2015). Sleep spindles and human cortical nociception: a surface and intracerebral
904 electrophysiological study. *J Physiol*, *593*(22), 4995-5008. doi: 10.1113/JP270941
- 905 Decosterd, I., & Woolf, C. J. (2000). Spared nerve injury: an animal model of persistent peripheral
906 neuropathic pain. *Pain*, *87*(2), 149-158. doi: 10.1016/s0304-3959(00)00276-1
- 907 Devor, M. (2009). Ectopic discharge in A β afferents as a source of neuropathic pain. *Exp Brain Res*,
908 *196*(1), 115-128. doi: 10.1007/s00221-009-1724-6
- 909 Dvir, H., Elbaz, I., Havlin, S., Appelbaum, L., Ivanov, P. C., & Bartsch, R. P. (2018). Neuronal noise as an
910 origin of sleep arousals and its role in sudden infant death syndrome. *Sci Adv*, *4*(4), eaar6277.
911 doi: 10.1126/sciadv.aar6277
- 912 Feige, B., Baglioni, C., Spiegelhalder, K., Hirscher, V., Nissen, C., & Riemann, D. (2013). The
913 microstructure of sleep in primary insomnia: an overview and extension. *Int J Psychophysiol*,
914 *89*(2), 171-180. doi: 10.1016/j.ijpsycho.2013.04.002
- 915 Feige, B., Nanovska, S., Baglioni, C., Bier, B., Cabrera, L., Diemers, S., Quellmalz, M., Siegel, M., Xeni, I.,
916 Szentkiralyi, A., Doerr, J. P., & Riemann, D. (2018). Insomnia-perchance a dream? Results from a
917 NREM/REM sleep awakening study in good sleepers and patients with insomnia. *Sleep*, *41*(5).
918 doi: 10.1093/sleep/zsy032
- 919 Fernandez, L. M., Vantomme, G., Osorio-Forero, A., Cardis, R., Béard, E., & Lüthi, A. (2018). Thalamic
920 reticular control of local sleep in sensory cortex. *Elife*, e39111. doi: doi: 10.7554/eLife.39111
- 921 Fernandez, L. M. J., Lecci, S., Cardis, R., Vantomme, G., Béard, E., & Lüthi, A. (2017). Quantifying infra-
922 slow dynamics of spectral power and heart rate in sleeping mice. *J Vis Exp*(126). doi:
923 10.3791/55863
- 924 Fernandez, L. M. J., & Lüthi, A. (2020). Sleep Spindles: Mechanisms and Functions. *Physiol Rev*, *100*(2),
925 805-868. doi: 10.1152/physrev.00042.2018

- 926 Finnerup, N. B., Attal, N., Haroutounian, S., McNicol, E., Baron, R., Dworkin, R. H., Gilron, I., Haanpaa, M.,
927 Hansson, P., Jensen, T. S., Kamerman, P. R., Lund, K., Moore, A., Raja, S. N., Rice, A. S.,
928 Rowbotham, M., Sena, E., Siddall, P., Smith, B. H., & Wallace, M. (2015). Pharmacotherapy for
929 neuropathic pain in adults: a systematic review and meta-analysis. *Lancet Neurol*, *14*(2), 162-
930 173. doi: 10.1016/S1474-4422(14)70251-0
- 931 Finnerup, N. B., Kuner, R., & Jensen, T. S. (2021). Neuropathic pain: from mechanisms to treatment.
932 *Physiol Rev*, *101*(1), 259-301. doi: 10.1152/physrev.00045.2019
- 933 Forget, D., Morin, C. M., & Bastien, C. H. (2011). The role of the spontaneous and evoked K-complex in
934 good-sleeper controls and in individuals with insomnia. *Sleep*, *34*(9), 1251-1260. doi:
935 10.5665/SLEEP.1250
- 936 Franken, P. (2002). Long-term vs. short-term processes regulating REM sleep. *J Sleep Res*, *11*(1), 17-28.
- 937 Franken, P., Malafosse, A., & Tafti, M. (1999). Genetic determinants of sleep regulation in inbred mice.
938 *Sleep*, *22*(2), 155-169.
- 939 Fulda, S. (2011). Idiopathic REM sleep behavior disorder as a long-term predictor of neurodegenerative
940 disorders. *EPMA J*, *2*(4), 451-458. doi: 10.1007/s13167-011-0096-8
- 941 Guida, F., De Gregorio, D., Palazzo, E., Ricciardi, F., Boccella, S., Belardo, C., Iannotta, M., Infantino, R.,
942 Formato, F., Marabese, I., Luongo, L., de Novellis, V., & Maione, S. (2020). Behavioral,
943 biochemical and electrophysiological changes in spared nerve injury model of neuropathic pain.
944 *Int J Mol Sci*, *21*(9). doi: 10.3390/ijms21093396
- 945 Hayat, H., Regev, N., Matosevich, N., Sales, A., Paredes-Rodriguez, E., Krom, A. J., Bergman, L., Li, Y.,
946 Lavigne, M., Kremer, E. J., Yizhar, O., Pickering, A. E., & Nir, Y. (2020). Locus coeruleus
947 norepinephrine activity mediates sensory-evoked awakenings from sleep. *Sci Adv*, *6*(15),
948 eaaz4232. doi: 10.1126/sciadv.aaz4232
- 949 Hohn, V. D., May, E. S., & Ploner, M. (2019). From correlation towards causality: modulating brain
950 rhythms of pain using transcranial alternating current stimulation. *Pain Rep*, *4*(4), e723. doi:
951 10.1097/PR9.0000000000000723
- 952 Huang, Z. L., Mochizuki, T., Qu, W. M., Hong, Z. Y., Watanabe, T., Urade, Y., & Hayaishi, O. (2006).
953 Altered sleep-wake characteristics and lack of arousal response to H3 receptor antagonist in
954 histamine H1 receptor knockout mice. *Proc Natl Acad Sci U S A*, *103*(12), 4687-4692. doi:
955 10.1073/pnas.0600451103

- 956 Iber, C., Ancoli-Israel, S., Chesson, A., & Quan, S. F. (2007). *The AASM manual for the scoring of sleep and*
957 *associated events: rules, terminology and technical specifications*. Westchester, IL: American
958 Academy of Sleep Medicine.
- 959 Kjaerby, C., Andersen, M., Hauglund, N., Ding, F., Wang, W., Xu, Q., Deng, S., Kang, N., Peng, S., Sun, Q.,
960 Dall, C., Jørgensen, P. K., Feng, J., Li, Y., Weikop, P., Hirase, H., & Nedergaard, M. (2020).
961 Dynamic fluctuations of the locus coeruleus-norepinephrine system underlie sleep state
962 transitions. *bioRxiv*, 2020.2009.2001.274977. doi: 10.1101/2020.09.01.274977
- 963 Kontinen, V. K., Ahnaou, A., Drinkenburg, W. H., & Meert, T. F. (2003). Sleep and EEG patterns in the
964 chronic constriction injury model of neuropathic pain. *Physiol Behav*, 78(2), 241-246. doi:
965 10.1016/s0031-9384(02)00966-6
- 966 Kopp, C., Longordo, F., Nicholson, J. R., & Lüthi, A. (2006). Insufficient sleep reversibly alters bidirectional
967 synaptic plasticity and NMDA receptor function. *J Neurosci*, 26(48), 12456-12465. doi:
968 10.1523/JNEUROSCI.2702-06.2006
- 969 Krystal, A. D., & Edinger, J. D. (2008). Measuring sleep quality. *Sleep Med*, 9 Suppl 1, S10-17. doi:
970 10.1016/S1389-9457(08)70011-X
- 971 Krystal, A. D., Edinger, J. D., Wohlgemuth, W. K., & Marsh, G. R. (2002). NREM sleep EEG frequency
972 spectral correlates of sleep complaints in primary insomnia subtypes. *Sleep*, 25(6), 630-640.
- 973 Kuner, R., & Kuner, T. (2020). Cellular circuits in the brain and their modulation in acute and chronic
974 pain. *Physiol Rev*. doi: 10.1152/physrev.00040.2019
- 975 Landis, C. A., Levine, J. D., & Robinson, C. R. (1989). Decreased slow-wave and paradoxical sleep in a rat
976 chronic pain model. *Sleep*, 12(2), 167-177. doi: 10.1093/sleep/12.2.167
- 977 LeBlanc, B. W., Lii, T. R., Silverman, A. E., Alleyne, R. T., & Saab, C. Y. (2014). Cortical theta is increased
978 while thalamocortical coherence is decreased in rat models of acute and chronic pain. *Pain*,
979 155(4), 773-782. doi: 10.1016/j.pain.2014.01.013
- 980 Lecci, S., Cataldi, J., Betta, M., Bernardi, G., Heinzer, R., & Siclari, F. (2020). EEG changes associated with
981 subjective under- and overestimation of sleep duration. *Sleep*, 43, zsa094. doi:
982 10.1093/sleep/zsa094
- 983 Lecci, S., Fernandez, L. M., Weber, F. D., Cardis, R., Chatton, J. Y., Born, J., & Lüthi, A. (2017). Coordinated
984 infraslow neural and cardiac oscillations mark fragility and offline periods in mammalian sleep.
985 *Sci Adv*, 3(2), e1602026. doi: 10.1126/sciadv.1602026

- 986 Léna, C., Popa, D., Grailhe, R., Escourrou, P., Changeux, J. P., & Adrien, J. (2004). β 2-containing nicotinic
987 receptors contribute to the organization of sleep and regulate putative micro-arousals in mice. *J*
988 *Neurosci*, *24*(25), 5711-5718. doi: 10.1523/JNEUROSCI.3882-03.2004
- 989 Leys, L. J., Chu, K. L., Xu, J., Pai, M., Yang, H. S., Robb, H. M., Jarvis, M. F., Radek, R. J., & McGaraughty, S.
990 (2013). Disturbances in slow-wave sleep are induced by models of bilateral inflammation,
991 neuropathic, and postoperative pain, but not osteoarthritic pain in rats. *Pain*, *154*(7), 1092-1102.
992 doi: 10.1016/j.pain.2013.03.019
- 993 Li, S. B., Borniger, J. C., Yamaguchi, H., Hedou, J., Gaudilliere, B., & de Lecea, L. (2020). Hypothalamic
994 circuitry underlying stress-induced insomnia and peripheral immunosuppression. *Sci Adv*, *6*(37).
995 doi: 10.1126/sciadv.abc2590
- 996 Lo, C. C., Chou, T., Penzel, T., Scammell, T. E., Strecker, R. E., Stanley, H. E., & Ivanov, P. (2004). Common
997 scale-invariant patterns of sleep-wake transitions across mammalian species. *Proc Natl Acad Sci*
998 *U S A*, *101*(50), 17545-17548. doi: 10.1073/pnas.0408242101
- 999 Maes, J., Verbraecken, J., Willemsen, M., De Volder, I., van Gastel, A., Michiels, N., Verbeek, I.,
1000 Vandekerckhove, M., Wuyts, J., Haex, B., Willemsen, T., Exadaktylos, V., Bulckaert, A., & Cluydts,
1001 R. (2014). Sleep misperception, EEG characteristics and autonomic nervous system activity in
1002 primary insomnia: a retrospective study on polysomnographic data. *Int J Psychophysiol*, *91*(3),
1003 163-171. doi: 10.1016/j.ijpsycho.2013.10.012
- 1004 Mang, G. M., & Franken, P. (2012). Sleep and EEG phenotyping in mice. *Curr Protoc Mouse Biol*, *2*(1), 55-
1005 74. doi: 10.1002/9780470942390.mo110126
- 1006 Mathias, J. L., Cant, M. L., & Burke, A. L. J. (2018). Sleep disturbances and sleep disorders in adults living
1007 with chronic pain: a meta-analysis. *Sleep Med*, *52*, 198-210. doi: 10.1016/j.sleep.2018.05.023
- 1008 May, E. S., Nickel, M. M., Ta Dinh, S., Tiemann, L., Heitmann, H., Voth, I., Tolle, T. R., Gross, J., & Ploner,
1009 M. (2019). Prefrontal gamma oscillations reflect ongoing pain intensity in chronic back pain
1010 patients. *Hum Brain Mapp*, *40*(1), 293-305. doi: 10.1002/hbm.24373
- 1011 Moisset, X., & Bouhassira, D. (2007). Brain imaging of neuropathic pain. *Neuroimage*, *37 Suppl 1*, S80-88.
1012 doi: 10.1016/j.neuroimage.2007.03.054
- 1013 Moldofsky, H., Scarisbrick, P., England, R., & Smythe, H. (1975). Musculoskeletal symptoms and non-
1014 REM sleep disturbance in patients with "fibrositis syndrome" and healthy subjects. *Psychosom*
1015 *Med*, *37*, 341-351.
- 1016 Neckelmann, D., & Ursin, R. (1993). Sleep stages and EEG power spectrum in relation to acoustical
1017 stimulus arousal threshold in the rat. *Sleep*, *16*(5), 467-477.

- 1018 Nickel, M. M., May, E. S., Tiemann, L., Postorino, M., Ta Dinh, S., & Ploner, M. (2017). Autonomic
1019 responses to tonic pain are more closely related to stimulus intensity than to pain intensity.
1020 *Pain*, 158(11), 2129-2136. doi: 10.1097/j.pain.0000000000001010
- 1021 Nobili, L., Ferrara, M., Moroni, F., De Gennaro, L., Russo, G. L., Campus, C., Cardinale, F., & De Carli, F.
1022 (2011). Dissociated wake-like and sleep-like electro-cortical activity during sleep. *Neuroimage*,
1023 58(2), 612-619. doi: 10.1016/j.neuroimage.2011.06.032
- 1024 Nollet, M., Hicks, H., McCarthy, A. P., Wu, H., Moller-Levet, C. S., Laing, E. E., Malki, K., Lawless, N.,
1025 Wafford, K. A., Dijk, D. J., & Winsky-Sommerer, R. (2019). REM sleep's unique associations with
1026 corticosterone regulation, apoptotic pathways, and behavior in chronic stress in mice. *Proc Natl*
1027 *Acad Sci U S A*, 116(7), 2733-2742. doi: 10.1073/pnas.1816456116
- 1028 Parrino, L., Milioli, G., De Paolis, F., Grassi, A., & Terzano, M. G. (2009). Paradoxical insomnia: the role of
1029 CAP and arousals in sleep misperception. *Sleep Med*, 10(10), 1139-1145. doi:
1030 10.1016/j.sleep.2008.12.014
- 1031 Perlis, M. L., Merica, H., Smith, M. T., & Giles, D. E. (2001a). Beta EEG activity and insomnia. *Sleep Med*
1032 *Rev*, 5(5), 363-374. doi: 10.1053/smr.2001.0151
- 1033 Perlis, M. T., Smith, M. T., Andrews, P. J., Orff, H., & Giles, D. E. (2001b). Beta/Gamma EEG activity in
1034 patients with primary and secondary insomnia and good sleeper controls. *Sleep*, 24(1), 110-117.
1035 doi: 10.1093/sleep/24.1.110
- 1036 Ploner, M., Sorg, C., & Gross, J. (2017). Brain rhythms of pain. *Trends Cogn Sci*, 21(2), 100-110. doi:
1037 10.1016/j.tics.2016.12.001
- 1038 Radzicki, D., Pollema-Mays, S. L., Sanz-Clemente, A., & Martina, M. (2017). Loss of M1 receptor
1039 dependent cholinergic excitation contributes to mPFC deactivation in neuropathic pain. *J*
1040 *Neurosci*, 37(9), 2292-2304. doi: 10.1523/JNEUROSCI.1553-16.2017
- 1041 Riedner, B. A., Goldstein, M. R., Plante, D. T., Rumble, M. E., Ferrarelli, F., Tononi, G., & Benca, R. M.
1042 (2016). Regional patterns of elevated alpha and high-frequency electroencephalographic activity
1043 during nonrapid eye movement sleep in chronic insomnia: a pilot study. *Sleep*, 39(4), 801-812.
1044 doi: 10.5665/sleep.5632
- 1045 Rolls, A., Colas, D., Adamantidis, A., Carter, M., Lanre-Amos, T., Heller, H. C., & de Lecea, L. (2011).
1046 Optogenetic disruption of sleep continuity impairs memory consolidation. *Proc Natl Acad Sci U S*
1047 *A*, 108(32), 13305-13310. doi: 10.1073/pnas.1015633108

- 1048 Salin-Pascual, R. J., Roehrs, T. A., Merlotti, L. A., Zorick, F., & Roth, T. (1992). Long-term study of the
1049 sleep of insomnia patients with sleep state misperception and other insomnia patients. *Am J*
1050 *Psychiatry*, *149*(7), 904-908. doi: 10.1176/ajp.149.7.904
- 1051 Sarnthein, J., Stern, J., Aufenberg, C., Rousson, V., & Jeanmonod, D. (2006). Increased EEG power and
1052 slowed dominant frequency in patients with neurogenic pain. *Brain*, *129*(Pt 1), 55-64. doi:
1053 10.1093/brain/awh631
- 1054 Schulz, E., May, E. S., Postorino, M., Tiemann, L., Nickel, M. M., Witkovsky, V., Schmidt, P., Gross, J., &
1055 Ploner, M. (2015). Prefrontal gamma oscillations encode tonic pain in humans. *Cereb Cortex*,
1056 *25*(11), 4407-4414. doi: 10.1093/cercor/bhv043
- 1057 Sforza, E., Jouny, C., & Ibanez, V. (2000). Cardiac activation during arousal in humans: further evidence
1058 for hierarchy in the arousal response. *Clin Neurophysiol*, *111*(9), 1611-1619. doi: 10.1016/s1388-
1059 2457(00)00363-1
- 1060 Shirvalkar, P., Veuthey, T. L., Dawes, H. E., & Chang, E. F. (2018). Closed-loop deep brain stimulation for
1061 refractory chronic pain. *Front Comput Neurosci*, *12*, 18. doi: 10.3389/fncom.2018.00018
- 1062 Silva, A., Andersen, M. L., & Tufik, S. (2008). Sleep pattern in an experimental model of osteoarthritis.
1063 *Pain*, *140*(3), 446-455. doi: 10.1016/j.pain.2008.09.025
- 1064 Silvani, A. (2019). Sleep disorders, nocturnal blood pressure, and cardiovascular risk: A translational
1065 perspective. *Auton Neurosci*, *218*, 31-42. doi: 10.1016/j.autneu.2019.02.006
- 1066 Spiegelhalder, K., Regen, W., Feige, B., Holz, J., Piosczyk, H., Baglioni, C., Riemann, D., & Nissen, C.
1067 (2012). Increased EEG sigma and beta power during NREM sleep in primary insomnia. *Biol*
1068 *Psychol*, *91*(3), 329-333. doi: 10.1016/j.biopsycho.2012.08.009
- 1069 St-Jean, G., Turcotte, I., & Bastien, C. H. (2012). Cerebral asymmetry in insomnia sufferers. *Front Neurol*,
1070 *3*, 47. doi: 10.3389/fneur.2012.00047
- 1071 Tan, L. L., Oswald, M. J., Heintz, C., Retana Romero, O. A., Kaushalya, S. K., Monyer, H., & Kuner, R. (2019).
1072 Gamma oscillations in somatosensory cortex recruit prefrontal and descending serotonergic
1073 pathways in aversion and nociception. *Nat Commun*, *10*(1), 983. doi: 10.1038/s41467-019-
1074 08873-z
- 1075 Tokunaga, S., Takeda, Y., Shinomiya, K., Yamamoto, W., Utsu, Y., Toide, K., & Kamei, C. (2007). Changes
1076 of sleep patterns in rats with chronic constriction injury under aversive conditions. *Biol Pharm*
1077 *Bull*, *30*(11), 2088-2090. doi: 10.1248/bpb.30.2088
- 1078 Treede, R. D., Rief, W., Barke, A., Aziz, Q., Bennett, M. I., Benoliel, R., Cohen, M., Evers, S., Finnerup, N.
1079 B., First, M. B., Giamberardino, M. A., Kaasa, S., Korwisi, B., Kosek, E., Lavand'homme, P.,


- 1080 Nicholas, M., Perrot, S., Scholz, J., Schug, S., Smith, B. H., Svensson, P., Vlaeyen, J. W. S., & Wang,
1081 S. J. (2019). Chronic pain as a symptom or a disease: the IASP Classification of Chronic Pain for
1082 the International Classification of Diseases (ICD-11). *Pain*, *160*(1), 19-27. doi:
1083 10.1097/j.pain.0000000000001384
- 1084 van Someren, E. J. W. (2020). Brain mechanisms of insomnia: new perspectives on causes and
1085 consequences. *Physiol Rev*, in press.
- 1086 Vargas, I., Nguyen, A. M., Muench, A., Bastien, C. H., Ellis, J. G., & Perlis, M. L. (2020). Acute and chronic
1087 insomnia: what has time and/or hyperarousal got to do with it? *Brain Sci*, *10*(2). doi:
1088 10.3390/brainsci10020071
- 1089 Vassalli, A., & Franken, P. (2017). Hypocretin (orexin) is critical in sustaining theta/gamma-rich waking
1090 behaviors that drive sleep need. *Proc Natl Acad Sci U S A*, *114*(27), E5464-E5473. doi:
1091 10.1073/pnas.1700983114
- 1092 Wall, P. D., & Devor, M. (1983). Sensory afferent impulses originate from dorsal root ganglia as well as
1093 from the periphery in normal and nerve injured rats. *Pain*, *17*(4), 321-339. doi: 10.1016/0304-
1094 3959(83)90164-1
- 1095 Wei, Y., Colombo, M. A., Ramautar, J. R., Blanken, T. F., van der Werf, Y. D., Spiegelhalder, K., Feige, B.,
1096 Riemann, D., & Van Someren, E. J. W. (2017). Sleep stage transition dynamics reveal specific
1097 stage 2 vulnerability in insomnia. *Sleep*, *40*(9). doi: 10.1093/sleep/zsx117
- 1098 Wimmer, R. D., Astori, S., Bond, C. T., Rovó, Z., Chatton, J. Y., Adelman, J. P., Franken, P., & Lüthi, A.
1099 (2012). Sustaining sleep spindles through enhanced SK2-channel activity consolidates sleep and
1100 elevates arousal threshold. *J Neurosci*, *32*(40), 13917-13928. doi: 10.1523/JNEUROSCI.2313-
1101 12.2012
- 1102 Yüzgeç, O., Prsa, M., Zimmermann, R., & Huber, D. (2018). Pupil size coupling to cortical states protects
1103 the stability of deep sleep via parasympathetic modulation. *Curr Biol*, *28*(3), 392-400 e393. doi:
1104 10.1016/j.cub.2017.12.049
- 1105 Zhang, Z., Gadotti, V. M., Chen, L., Souza, I. A., Stemkowski, P. L., & Zamponi, G. W. (2015). Role of
1106 prelimbic GABAergic circuits in sensory and emotional aspects of neuropathic pain. *Cell Rep*,
1107 *12*(5), 752-759. doi: 10.1016/j.celrep.2015.07.001

1108


1109

1110

1111 Supplementary figures




1113 **Figure 2 – figure supplement 1** – Methodological illustration of how to extract the 0.02 Hz-fluctuation
1114 from raw signals, to detect individual cycles, and to calculate the angles of the Hilbert transform. **(A)** 12-
1115 h hypnogram obtained from visual scoring of EEG/EMG recordings. W, wakefulness; N, NREMS; R, REMS.
1116 **(B)** Corresponding EEG signal. **(C)** Corresponding mean Morlet wavelet transform, calculated in 0.5-Hz
1117 frequency bins from 10–15 Hz. **(D)** Corresponding 0.02 Hz-fluctuation, obtained through downsampling
1118 to 10 Hz and lowpass filtering. Normalization was done by dividing the signal by its mean value in NREMS.
1119 **(E)** Result of cycle detection on the signal shown in D, using the peak-and-trough detection approach
1120 described in the Methods. The beginning, peak and end of each cycle is shown with color-coded circles.
1121 **(F)** Angle of the Hilbert transform of the signal shown D. The values are wrapped around 360° with 180°
1122 representing the troughs of the fluctuation. **(G)** Expansion of the grey area highlighted for D, E, F and A.
1123 **(H)** Histogram showing the phase constitution of the 0.02 Hz-fluctuation. Note the prominence from 180–
1124 360°, indicating more time spent in ascending period compared to descending. A sinusoid would yield the
1125 same amount of points within each phase bin. Therefore, we now talk about 0.02 Hz-fluctuation and not
1126 oscillation as in (Lecci et al., 2017).



1127

1128 **Figure 5 – figure supplement 2 – Activation index (AI) with peaks in fragility period are also present in EEG**
 1129 **and PrL but occur in equal amounts in Sham or SNI. (A) Left, Proportion of fragility periods containing an**
 1130 **AI peak over the 12-h light phase, detected in the frontoparietal EEG (contralateral to Sham or SNI**
 1131 **surgeries) in the subset of animals from which the S1HL data were obtained in figure 5; sum rank test**
 1132 **Sham vs SNI: $W = 10$, $p = 0.76$. The data from 1 Sham and 3 SNI animals were left out because the EEG was**
 1133 **implanted ipsilateral to Sham or SNI surgeries. Middle: mean amplitude (green triangle in the inset) of the**
 1134 **AI peaks in the EEG (S1HL subset), with or without the presence of a MA in the fragility period, in Sham**
 1135 **and SNI. Mixed-model ANOVA: $F_{(1,8)} = 0.03$, $p = 0.85$ for ‘treatment’; $F_{(1,8)} = 224.9$, $p = 3.8 \times 10^{-7}$ for ‘MA’;**
 1136 **$F_{(1,8)} = 6.83$, $p = 0.03$ for interaction. *Post-hoc* rank sum test for Sham vs SNI for fragility periods with a MA:**
 1137 **$W = 9$, $p = 0.6$; for fragility periods without a MA: $W = 13$, $p = 0.91$; signed rank test with vs without MA in**
 1138 **Sham: $V = 10$, $p = 0.12$; in SNI: $V = 21$, $p = 0.03$; $\alpha = 0.0125$. Right: half width duration (green line in the**
 1139 **inset) of the AI peaks in the EEG (S1HL subset), with or without the presence of a MA in the fragility period,**
 1140 **in Sham and SNI. Mixed-model ANOVA: $F_{(1,8)} = 2.06$, $p = 0.18$ for ‘treatment’; $F_{(1,8)} = 39.12$, $p = 2.4 \times 10^{-4}$ for**

1141 'MA'; $F_{(1,8)} = 0.91$, $p = 0.36$ for interaction. **(B)** Same layout as in A. Data from the frontoparietal EEG
1142 (contralateral to Sham or SNI surgeries) from all our animals; Left: proportion of fragility periods
1143 containing an AI peak, over time and 12 h quantification: unpaired t -tests Sham vs SNI: $t_{(21)} = -0.5$, $p = 0.62$.
1144 Middle: mean amplitude of the AI peaks in the EEG with or without the presence of a MA in the fragility
1145 period, in Sham and SNI. Mixed-model ANOVA: $F_{(1,21)} = 0.81$, $p = 0.37$ for 'treatment'; $F_{(1,21)} = 446.8$, $p =$
1146 1.23×10^{-15} for 'MA'; $F_{(1,21)} = 1.64$, $p = 0.21$ for interaction. Right: duration at half-maximal amplitude of the
1147 AI peaks in the EEG, with or without the presence of a MA in the fragility period, in Sham and SNI. Mixed-
1148 model ANOVA: $F_{(1,21)} = 0.29$, $p = 0.59$ for 'treatment'; $F_{(1,21)} = 174.9$, $p = 1.2 \times 10^{-11}$ for 'MA'; $F_{(1,21)} = 0.03$, $p =$
1149 0.85 for interaction. **(C)** Same layout as in A and B. Data from the PrL cortex; Left: proportion of fragility
1150 periods containing an AI peak, over time and 12 h quantification: unpaired t -tests Sham vs SNI: $t_{(12)} = -$
1151 0.23 , $p = 0.82$. Middle: mean amplitude of the AI peaks in PrL with or without the presence of a MA in the
1152 fragility period, in Sham and SNI. Mixed-model ANOVA: $F_{(1,12)} = 0.89$, $p = 0.36$ for 'treatment'; $F_{(1,12)} = 63.9$,
1153 $p = 3.7 \times 10^{-6}$ for 'MA'; $F_{(1,12)} = 0.74$, $p = 0.4$ for interaction. Right: duration at half-maximal amplitude of the
1154 AI peaks in the EEG, with or without the presence of a MA in the fragility period, in Sham and SNI. Mixed-
1155 model ANOVA: $F_{(1,12)} = 1.84$, $p = 0.19$ for 'treatment'; $F_{(1,12)} = 50.26$, $p = 1.2 \times 10^{-5}$ for 'MA'; $F_{(1,12)} = 1.71$, $p =$
1156 0.21 for interaction.



1169

1170 **Figure 7 – figure supplement 4 – Vibration motor calibration for closed-loop somatosensory arousability**
1171 **testing. (A)** Photo overview of the calibration setup, showing the vibration motor positioned onto a self-
1172 made piezometer containing the sensor (bottom right). The analog voltage generated by the sensor was
1173 measured by an Arduino and data fed into Matlab. To start vibrations, a raspberry pi sent a PWM signal
1174 to the vibration motor to modulate vibration intensity (achieved through increasing duty cycle from 15
1175 to 50 %). A TTL signal sent from the raspberry pi to the Arduino initiated the trial. **(B)** Close-up view of the
1176 self-made piezometer. The piezometer was composed of protective foam sandwiched and glued between
1177 two thin wooden plates. The upper plate contained a hole the size of the vibration motors and the lower
1178 one was fixed to the table using two-sided adhesive tape. The piezo sensor was inserted inside the foam
1179 part and a resistance (1000 Ohm) was used in the circuit. **(C)** Plot of data received from one vibration
1180 measurement trial. The vibration curve was calculated from each trial using whole-power wavelet
1181 transform. **(D)** Calibration curve (mean of 15 trials) used to find the necessary duty-cycle value. The chosen
1182 intensity was the same for all the motors.

1183